BioMedLib Search Engine [ goto HOMEPAGE ]

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Immunohistochemistry in oligodendrogliomas].

[Transliterated title] Imunoistoquímica em oligodendrogliomas.

Oligodendrogliomas (OL) are neuroepithelial tumors characterized by the presence of uniformly round nuclei with a clear cytoplasm around it.

These features can also be seen in central neurocytomas, DNTs and clear cell ependymomas.

The widespread staining with neuronal marker suggests central neurocytoma, but this diagnosis should not be done with small amount of tissue.

[MeSH-major] Antibodies, Neoplasm / analysis. Brain Neoplasms / pathology. Neuroglia / pathology. Oligodendroglioma / pathology

[MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / immunology. Biomarkers, Tumor / metabolism. Child. Child, Preschool. Humans. Immunohistochemistry. Male. Middle Aged. S100 Proteins / analysis. S100 Proteins / immunology

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16622556.001).

[ISSN] 0004-282X

[Journal-full-title] Arquivos de neuro-psiquiatria

[ISO-abbreviation] Arq Neuropsiquiatr

[Language] por

[Publication-type] English Abstract; Journal Article

[Publication-country] Brazil

[Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Biomarkers, Tumor; 0 / S100 Proteins

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Toward improved grading of malignancy in oligodendrogliomas using metabolomics.

In spite of having been the object of considerable attention, the histopathological grading of oligodendrogliomas is still controversial.

Therefore the metabolome of 34 human brain biopsies, histopathologically classified as low-grade (LGO, N = 10) and high-grade (HGO, N = 24) oligodendrogliomas, was studied using high-resolution magic angle spinning nuclear magnetic resonance spectroscopy (HRMAS NMR) and multivariate statistical analysis.

The statistical model was then used to study biopsy samples that were classified as intermediate oligodendrogliomas (N = 6) and glioblastomas (GBMs) (N = 30) by histopathology.

The results revealed a gradient of tumoral hypoxia increasing in the following direction: LGOs, intermediate oligodendrogliomas, HGOs, and GBMs.

[MeSH-major] Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Glioblastoma / metabolism. Glioblastoma / pathology. Magnetic Resonance Spectroscopy / methods. Neoplasm Staging / methods. Oligodendroglioma / metabolism. Oligodendroglioma / pathology

[MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Models, Statistical. Prospective Studies

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] (c) 2008 Wiley-Liss, Inc.

(PMID = 18429037.001).

[ISSN] 0740-3194

[Journal-full-title] Magnetic resonance in medicine

[ISO-abbreviation] Magn Reson Med

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Longitudinal assessment of genetic and epigenetic markers in oligodendrogliomas.

PURPOSE: Because little is known about the evolution of genetic and epigenetic changes that occur during tumor progression in oligodendrogliomas, we evaluated these changes in paired early and progressive oligodendrogliomas.

EXPERIMENTAL DESIGN: 1p36, 19q13, 10q22-26, and O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation status were assessed in 46 paired early and progressive oligodendrogliomas from 23 patients.

RESULTS: In early tumors, 60.8% were of low grade compared with only 17% low-grade tumors at recurrence.

Of 17 early tumors described as pure oligodendrogliomas, 76.5% remained in this lineage, regardless of their grade, whereas others changed to astrocytic tumors.

All pure oligodendrogliomas with 1p/19q codeletions remained phenotypically unchanged, unlike mixed tumors with codeletions, of which 83% changed their cell lineage.

Of tumors with early 1p deletion, 80% remained oligodendroglial at progression, whereas 75% of tumors with an intact 1p changed to astrocytic phenotype.

CONCLUSIONS: Pure oligodendrogliomas with 1p/19q deletion tend to retain their cell phenotype and genetic profile unlike tumors with no deletions or mixed histology.

MGMT promoter methylation is more pronounced at tumor progression, particularly in tumors with an intact 1p.

These observations suggest that MGMT promoter methylation is a late event in progressive oligodendrogliomas, and therefore, their chemosensitivity is not necessarily related to MGMT methylation status.

[MeSH-major] Brain Neoplasms / genetics. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. DNA Methylation. Epigenesis, Genetic. Oligodendroglioma / genetics

[MeSH-minor] Adolescent. Adult. Aged. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Female. Humans. Immunohistochemistry. Male. Microsatellite Repeats. Middle Aged. Phenotype. Polymerase Chain Reaction. Promoter Regions, Genetic. Tumor Suppressor Proteins / genetics

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17332285.001).

[ISSN] 1078-0432

[Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research

[ISO-abbreviation] Clin. Cancer Res.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Tumor Suppressor Proteins; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes

   

Advertisement

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Losses of chromosomes 1p and 19q are rare in pediatric oligodendrogliomas.

Pediatric oligodendrogliomas are rare neoplasms and have not been characterized extensively either pathologically or genetically.

Given the recent interest in the significance of chromosomal losses in predicting the clinical course and in establishing uniform diagnoses of adult oligodendrogliomas, we reviewed the pathological and clinical features of a series of pediatric oligodendrogliomas and determined their 1p and 19q status using fluorescence in situ hybridization.

Of 19 tumors originally diagnosed as oligodendroglioma, 7 were oligodendroglioma, 3 were anaplastic oligodendroglioma, 3 were oligoastrocytoma, and 6 were reclassified.

Only one tumor, an anaplastic oligodendroglioma, had 1p loss; none had 19q loss.

The single patient whose tumor had 1p loss did not have a particularly favorable clinical course.

These results suggest that pediatric oligodendrogliomas arise by molecular alterations distinct from adult oligodendrogliomas, and such molecular alterations do not hold immediate promise as an adjunct to the diagnosis of pediatric oligodendrogliomas.

[MeSH-major] Brain Neoplasms / genetics. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. Oligodendroglioma / genetics

[MeSH-minor] Actins / metabolism. Adolescent. Adult. Antigens, CD20 / metabolism. Antigens, CD45 / metabolism. Cell Count / methods. Child. Child, Preschool. Female. Follow-Up Studies. Glial Fibrillary Acidic Protein / metabolism. Humans. Immunohistochemistry / methods. In Situ Hybridization / methods. Infant, Newborn. Ki-67 Antigen / metabolism. Male. Neurofilament Proteins / metabolism. Synaptophysin / metabolism. Vimentin / metabolism

MedlinePlus Health Information. consumer health - Brain Tumors.

MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15739101.001).

[ISSN] 0001-6322

[Journal-full-title] Acta neuropathologica

[ISO-abbreviation] Acta Neuropathol.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / CA57683

[Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.

[Publication-country] Germany

[Chemical-registry-number] 0 / Actins; 0 / Antigens, CD20; 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen; 0 / Neurofilament Proteins; 0 / Synaptophysin; 0 / Vimentin; EC 3.1.3.48 / Antigens, CD45

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Metabolic imaging for supratentorial oligodendrogliomas].

Only a few publications have yet reported its use in oligodendroglial tumors.

These findings and partial results obtained in ongoing work, suggest some preliminary conclusions: 11C-MET (L-methyl-methionine) is a more appropriate tracer than 18F-FDG (fluoro-deoxy-glucose), in terms of both specificity and sensitivity, for the assessment of patients with this category of tumor.

PET/MET allows differentiation between grade II and grade III oligodendrogliomas; better targeting for stereotactic biopsy; more accurate assessment of the post-operative residual tumor; identification of progression from low-grade to anaplastic grade during the disease course; differentiation between recurrence and a post-radiation processes.

[MeSH-major] Brain. Oligodendroglioma / metabolism. Positron-Emission Tomography. Supratentorial Neoplasms / metabolism

[MeSH-minor] Adult. Amino Acids / metabolism. Female. Glucose / metabolism. Glycolysis. Humans. Imaging, Three-Dimensional. Magnetic Resonance Imaging. Male. Methionine / analogs & derivatives. Methionine / pharmacokinetics. Radioactive Tracers. Tomography, X-Ray Computed

Hazardous Substances Data Bank. GLUCOSE .

Hazardous Substances Data Bank. (L)-Methionine .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16292175.001).

[ISSN] 0028-3770

[Journal-full-title] Neuro-Chirurgie

[ISO-abbreviation] Neurochirurgie

[Language] fre

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] France

[Chemical-registry-number] 0 / Amino Acids; 0 / Radioactive Tracers; AE28F7PNPL / Methionine; BN630929UL / methionine methyl ester; IY9XDZ35W2 / Glucose

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Can tumor contrast enhancement be used as a criterion for differentiating tumor grades of oligodendrogliomas?

BACKGROUND AND PURPOSE: The association of high-grade oligodendrogliomas with tumor contrast material enhancement on MR images has been reported.

Some authors have even used contrast enhancement as a criterion for their oligodendroglioma grading system.

The purpose of our study was to evaluate if tumor contrast enhancement is a specific finding for anaplastic oligodendroglioma.

METHODS: Pretreatment MR images of 24 oligodendrogliomas were reviewed retrospectively, and findings were compared with the histologic grade.

The presence or absence and the pattern of tumor contrast enhancement were evaluated qualitatively.

A contrast enhancement ratio (CER), a quantitative criterion, was calculated to assess the difference in degree of enhancement between the low-grade and anaplastic tumors.

Tumor grade was diagnosed at pathologic examination according to the World Health Organization classification system.

RESULTS: Contrast enhancement was noted in nine (56%) of 16 low-grade tumors and in five (62%) of eight anaplastic tumors.

The CERs were 2.12-40.88 (mean, 20.08) in low-grade tumors and were 3.20-62.52 (mean, 28.73) in anaplastic tumors (P > .05).

CONCLUSION: Tumor contrast enhancement was not statistically significantly different between the tumor groups.

We believe that the presence or absence of tumor contrast enhancement is not a specific finding for simply discriminating low-grade from anaplastic oligodendrogliomas.

[MeSH-major] Brain Neoplasms / pathology. Magnetic Resonance Imaging. Oligodendroglioma / pathology

[MeSH-minor] Adolescent. Adult. Aged. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Retrospective Studies

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15814921.001).

[ISSN] 0195-6108

[Journal-full-title] AJNR. American journal of neuroradiology

[ISO-abbreviation] AJNR Am J Neuroradiol

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.

IDH1 mutations were frequent in low-grade diffuse astrocytomas (88%) and in secondary glioblastomas that developed through progression from low-grade diffuse or anaplastic astrocytoma (82%).

Similarly, high frequencies of IDH1 mutations were found in oligodendrogliomas (79%) and oligoastrocytomas (94%).

IDH1 mutations were co-present with TP53 mutations in 63% of low-grade diffuse astrocytomas and with loss of heterozygosity 1p/19q in 64% of oligodendrogliomas; they were rare in pilocytic astrocytomas (10%) and primary glioblastomas (5%) and absent in ependymomas.

[MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Isocitrate Dehydrogenase / genetics. Oligodendroglioma / genetics

[MeSH-minor] Adult. Age Factors. Biomarkers, Tumor / genetics. Female. Humans. Male. Middle Aged. Mutation. Polymorphism, Single-Stranded Conformational. Tumor Suppressor Protein p53 / genetics

MedlinePlus Health Information. consumer health - Brain Tumors.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Lab Invest. 2000 Jan;80(1):65-72 [10653004.001]

[Cites] J Neuropathol Exp Neurol. 1997 Oct;56(10):1098-104 [9329453.001]

[Cites] Acta Neuropathol. 2002 Mar;103(3):267-75 [11907807.001]

[Cites] Am J Pathol. 2002 Jul;161(1):313-9 [12107116.001]

[Cites] J Neuropathol Exp Neurol. 2003 Feb;62(2):111-26 [12578221.001]

[Cites] J Neurosurg. 2003 Jun;98(6):1170-4 [12816259.001]

[Cites] Acta Neuropathol. 2004 Jul;108(1):49-56 [15118874.001]

[Cites] Clin Cancer Res. 1997 Apr;3(4):523-30 [9815715.001]

[Cites] J Biol Chem. 1999 Oct 22;274(43):30527-33 [10521434.001]

[Cites] Lab Invest. 2005 Feb;85(2):165-75 [15592495.001]

[Cites] J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89 [15977639.001]

[Cites] Am J Pathol. 2007 May;170(5):1445-53 [17456751.001]

[Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]

[Cites] J Neuropathol Exp Neurol. 2008 Sep;67(9):878-87 [18716556.001]

[Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]

[Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]

[Cites] Hum Genet. 1985;71(1):37-40 [3861566.001]

[Cites] Carcinogenesis. 2001 Oct;22(10):1715-9 [11577014.001]

(PMID = 19246647.001).

[ISSN] 1525-2191

[Journal-full-title] The American journal of pathology

[ISO-abbreviation] Am. J. Pathol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53; EC 1.1.1.41 / Isocitrate Dehydrogenase

[Other-IDs] NLM/ PMC2671348

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Quantitative proteomic analysis of oligodendrogliomas with and without 1p/19q deletion.

Approximately 50-80% of oligodendrogliomas demonstrate a combined loss of chromosome 1p and 19q.

Although many hypotheses have been proposed, the molecular mechanisms underlying improved clinical outcomes with 1p/19q deletion in oligodendrogliomas have not been characterized fully.

To investigate the molecular differences between oligodendrogliomas, we employed an unbiased proteomic approach using microcapillary liquid chromatography mass spectrometry, along with a quantitative technique called isotope-coded affinity tags, on patient samples of grade II oligodendrogliomas.

Following conventional biochemical separation of pooled tumor tissue from five samples of undeleted and 1p/19q deleted grade II oligodendrogliomas into nuclei-, mitochondria-, and cytosol-enriched fractions, relative changes in protein abundance were quantified.

Among the 442 total proteins identified, 163 nonredundant proteins displayed significant changes in relative abundance in at least one of the three fractions between oligodendroglioma with and without 1p/19q deletion.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Neurooncol. 2009 Dec;95(3):343-54 [19597701.001]

[Cites] Am J Pathol. 2009 Jul;175(1):54-65 [19498008.001]

[Cites] J Biol Chem. 2000 Jul 28;275(30):22695-703 [10801887.001]

[Cites] Clin Cancer Res. 2001 Apr;7(4):839-45 [11309331.001]

[Cites] J Neurosci Methods. 2001 Aug 15;109(1):3-11 [11489294.001]

[Cites] Electrophoresis. 2002 Jan;23(2):311-28 [11840540.001]

[Cites] Genome Res. 2002 Aug;12(8):1231-45 [12176931.001]

[Cites] Anal Chem. 2002 Oct 15;74(20):5383-92 [12403597.001]

[Cites] J Neuropathol Exp Neurol. 2003 Feb;62(2):111-26 [12578221.001]

[Cites] Glia. 2003 Apr 15;42(2):194-208 [12655603.001]

[Cites] J Clin Oncol. 2003 Apr 15;21(8):1624-36 [12697889.001]

[Cites] Anal Chem. 2003 Dec 1;75(23):6648-57 [14640741.001]

[Cites] Brain Tumor Pathol. 2003;20(2):53-8 [14756441.001]

[Cites] Brain Pathol. 2004 Jan;14(1):34-42 [14997935.001]

[Cites] J Biol Chem. 2004 Sep 10;279(37):39155-64 [15234983.001]

[Cites] Genome Biol. 2004;5(10):R80 [15461798.001]

[Cites] Ann Neurol. 1988 Apr;23(4):360-4 [3382171.001]

[Cites] Cancer Res. 1990 Oct 15;50(20):6696-700 [2208135.001]

[Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]

[Cites] Nat Biotechnol. 1999 Jul;17(7):676-82 [10404161.001]

[Cites] Nat Biotechnol. 1999 Oct;17(10):994-9 [10504701.001]

[Cites] Neurobiol Aging. 2005 Feb;26(2):207-27 [15582749.001]

[Cites] Brain Res Mol Brain Res. 2005 Mar 24;134(1):119-38 [15790536.001]

[Cites] J Alzheimers Dis. 2005 Apr;7(2):125-33; discussion 173-80 [15851850.001]

[Cites] Ann Neurol. 2005 Jun;57(6):855-65 [15929038.001]

[Cites] Cancer Res. 2005 Aug 1;65(15):6726-33 [16061654.001]

[Cites] Acta Neuropathol. 2005 Sep;110(3):239-46 [16133547.001]

[Cites] Science. 2006 Apr 14;312(5771):212-7 [16614208.001]

[Cites] J Neurosurg. 2006 Apr;104(4):542-50 [16619658.001]

[Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]

[Cites] Bioinformatics. 2006 Jul 1;22(13):1600-7 [16606683.001]

[Cites] Mol Cell Proteomics. 2006 Jul;5(7):1193-204 [16565515.001]

[Cites] J Alzheimers Dis. 2006 Aug;9(3):293-348 [16914840.001]

[Cites] Proteomics. 2007 Feb;7(3):469-73 [17211832.001]

[Cites] Cancer Biol Ther. 2007 Mar;6(3):391-6 [17264672.001]

[Cites] Mol Cell Proteomics. 2007 Oct;6(10):1818-23 [17644759.001]

[Cites] Clin Cancer Res. 2007 Dec 1;13(23):6933-7 [18056167.001]

[Cites] Neoplasia. 2008 Feb;10(2):149-59 [18283337.001]

[Cites] J Neuropathol Exp Neurol. 2008 Feb;67(2):117-24 [18219256.001]

[Cites] J Neurooncol. 2008 Jul;88(3):261-72 [18398576.001]

[Cites] Cancer Cell. 2008 Jun;13(6):472-82 [18538731.001]

[Cites] Mol Cancer. 2008;7:41 [18492260.001]

[Cites] Neuropathology. 2008 Aug;28(4):382-6 [18298442.001]

[Cites] J Biol Chem. 2008 Sep 5;283(36):24848-59 [18611854.001]

[Cites] Neurology. 2009 Jan 13;72(2):156-61 [19139367.001]

[Cites] J Mol Med (Berl). 2009 Feb;87(2):153-67 [19066835.001]

[Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]

(PMID = 20337498.001).

[ISSN] 1535-3907

[Journal-full-title] Journal of proteome research

[ISO-abbreviation] J. Proteome Res.

[Language] ENG

[Grant] United States / NINDS NIH HHS / NS / T32 NS007144; None / None / / T32 NS007144-28; United States / NINDS NIH HHS / NS / T32 NS0007144; United States / NINDS NIH HHS / NS / T32 NS007144-28

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Other-IDs] NLM/ NIHMS302192; NLM/ PMC3119493

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Proteomic comparison of oligodendrogliomas with and without 1pLOH.

Oligodendrogliomas provide a unique model to study the molecular basis of chemoresistance, as there are two distinct genetic subtypes with significant differences in chemosensitivity.

METHODS: In order to identify candidate proteins potentially responsible for glioma chemosensitivity, we compared the proteome of four oligodendrogliomas with and five without 1pLOH using comparative proteomic profiling.

RESULTS: We identified seven candidate proteins that are overexpressed in oligodendrogliomas without 1pLOH.

CONCLUSIONS: These identified proteins are potential targets for pharmacological therapy and may also be useful as biomarkers for differentiation of chemoresistant and chemosensitive oligodendroglioma.

[MeSH-major] Brain Neoplasms / metabolism. Chromosomes, Human, Pair 1 / genetics. Drug Resistance, Neoplasm / genetics. Loss of Heterozygosity. Neoplasm Proteins / analysis. Oligodendroglioma / metabolism. Proteome / genetics

[MeSH-minor] Adult. Aged. Blotting, Western. Electrophoresis, Gel, Two-Dimensional. Female. Humans. Male. Middle Aged. Proteomics

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17264672.001).

[ISSN] 1538-4047

[Journal-full-title] Cancer biology & therapy

[ISO-abbreviation] Cancer Biol. Ther.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / CA095809-04; United States / Intramural NIH HHS / /

[Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural

[Publication-country] United States

[Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Proteome

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Adult supratentorial oligodendrogliomas. Surgical treatment: indications and techniques].

[Transliterated title] Oligodendrogliomes supratentoriels de l'adulte. Traitement chirurgical: indications et techniques.

Surgical resection is the first step in the treatment of adult supratentorial oligodendrogliomas (OLG).

Surgical or stereotactic biopsy is the first surgical procedure which enables confirmation of the diagnosis suggested on imaging, assessment of extension of tumor cell infiltration beyond abnormalities limit described an imaging, and currently available molecular biology studies.

Biopsies may be the only surgical procedure in patients having a deep-seated tumor with minimal mass effect, or prior to a surgical resection or a "wait and watch" strategy.

A wait and watch strategy is therefore warranted in patients with a tumor aspect suggestive of a grade A OLG; surgical resection may be indicated later.

There is a current trend for maximal safe resection, preserving functional cerebral areas, since truly complete resection of the tumor including infiltration is exceptional.

[MeSH-major] Neurosurgical Procedures / methods. Oligodendroglioma / surgery. Supratentorial Neoplasms / surgery

[MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Karnofsky Performance Status. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Time Factors

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16292178.001).

[ISSN] 0028-3770

[Journal-full-title] Neuro-Chirurgie

[ISO-abbreviation] Neurochirurgie

[Language] fre

[Publication-type] English Abstract; Journal Article

[Publication-country] France

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Spatial delimitation of low grade oligodendrogliomas].

[Transliterated title] Délimitation spatiale des oligodendrogliomes de bas grade.

Image-guided surgery is the central element of therapeutic management of low grade gliomas and consequently, a precise preoperative definition of their spatial extension is necessary.

The question of the present work is: do the imaging abnormalities delineate the real spatial development of low grade oligodendrogliomas?

Moreover, mathematical models and histological studies suggest that MRI does not indicate the actual spatial extension of low grade oligodendrogliomas.

This study focused on histological analysis of biopsy samples performed outside MRI imaging abnormalities in patients who harboured a low grade oligodendroglioma.

Thus, conventional imaging findings, including MRI on T2-weighted and FLAIR sequences, are not able to provide the real spatial development and boundaries of low grade oligodendrogliomas.

[MeSH-major] Brain Neoplasms / pathology. Neoplasm Invasiveness. Oligodendroglioma / pathology

[MeSH-minor] Adolescent. Adult. Biopsy. Brain / pathology. Brain / surgery. Female. Humans. Magnetic Resonance Spectroscopy. Male. Middle Aged. Neoplasm Staging. Preoperative Care. Radiopharmaceuticals. Retrospective Studies. Technetium Tc 99m Sestamibi

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16292169.001).

[ISSN] 0028-3770

[Journal-full-title] Neuro-Chirurgie

[ISO-abbreviation] Neurochirurgie

[Language] fre

[Publication-type] English Abstract; Journal Article

[Publication-country] France

[Chemical-registry-number] 0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Neuronal features of oligodendrogliomas--an ultrastructural and immunohistochemical study.

AIMS: To assess neuronal differentiation in oligodendrogliomas (ODGs).

[MeSH-major] Cell Transformation, Neoplastic / pathology. Central Nervous System Neoplasms / pathology. Neurons / pathology. Oligodendroglioma / pathology

[MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Biomarkers, Tumor / genetics. DNA, Neoplasm / analysis. Female. Fluorescent Antibody Technique, Direct. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Male. Microscopy, Electron, Transmission. Middle Aged

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17543079.001).

[ISSN] 0309-0167

[Journal-full-title] Histopathology

[ISO-abbreviation] Histopathology

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Oligodendrogliomas in relation to astrocytes differentiation. Clinicopathologic and immunohistochemical study.

Oligodendroglioma usually arise in adults and rarely in children.

The objective of the current study was to evaluate the immunoexpression of glial fibrillary acidic protein (GFAP) and heat shock proteins (HSP70), endothelial vascular growth factor (EVGF), and endothilial vascular growth factor receptor type II (EFGF-R) expression in relation to the proliferation labeling index (proliferating cell nuclear antigen [PCNA]) and vascular density in patients with oligodendroglioma.

We studied 28 cases of oligodendrogliomas--20 (71.4%) were oliodendrogliomas (grade II), and 8 (28.6%) cases were anaplastic oligodendroglioma (grade II according to World Health Organization classification).

Mitosis were found in grade II (0.35 +/- 1.14) and grade III (3.88 +/- 1.81) (P = .0001*) and pleomorphism in grade II (4.40 +/- 0.99) and grade III (9.50 +/- 9.20) (P = .028).

The GFAP was positive in grade II (1.45 +/- 0.60) and grade III (2.63 +/- 0.52) (P = .000); HSP70 was immunoreactive in grade II (1.35 +/- 0.59) and grade III (2.50 +/- 0.53) (P = .001); and EVGF was immunoreactive in grade II (22.70 +/- 6.10) and grade III (36 +/- 1.63) (P = .043).

The EVGF-RII was immunoreactive in grade II, 18.30 +/- 6.11 and 31.63 +/- 4.93 (P = .045).

The microvascular density labeling index rates were 20.70 +/- 4.34 (grade II) and 33.38 +/- 5.29 (P = .000), and the PCNA labeling index rates were 32.95 +/- 5.89 (grade II) and 56.88 +/- 5.62 (grade III) (P = .045).

We observed astrocyte differentiation in oligodendrogliomas grade III.

We found a higher PGAF, HSP70, EVGF, and EFGF-R expression in relation with the PCNA and vascular density (CD34) in patients with oligodendroglioma grade III than in oligodendroglioma grade II.

There was a significant relationship between mitosis, glial fibrillary acidic protein (GFAP), HSP70, EVGF, EVGF-receptor II expression, and the histologic grade and size of the tumor.

For that reason, we suggest that the correlation between GFAP and HSP70 could have a relationship with the protection mechanism of the tumor itself.

[MeSH-major] Astrocytes / pathology. Brain Neoplasms / pathology. Oligodendroglioma / pathology

[MeSH-minor] Adolescent. Adult. Aged. Antigens, CD34 / analysis. Biomarkers, Tumor / analysis. Cell Proliferation. Cell Transformation, Neoplastic. Female. Fluorescent Antibody Technique, Direct. Glial Fibrillary Acidic Protein / analysis. HSP70 Heat-Shock Proteins / analysis. Humans. Male. Middle Aged. Mitosis. Proliferating Cell Nuclear Antigen / metabolism. Vascular Endothelial Growth Factor A / analysis. Vascular Endothelial Growth Factor Receptor-2 / analysis

MedlinePlus Health Information. consumer health - Brain Tumors.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18774492.001).

[ISSN] 1532-8198

[Journal-full-title] Annals of diagnostic pathology

[ISO-abbreviation] Ann Diagn Pathol

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / Glial Fibrillary Acidic Protein; 0 / HSP70 Heat-Shock Proteins; 0 / Proliferating Cell Nuclear Antigen; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Long-term results of treatment in patients with oligodendrogliomas and oligoastrocytomas of the cerebral hemispheres].

BACKGROUND: the current approach to treating patients with cerebral oligodendrogliomas and oligoastrocytomas involves surgical treatment with the maximum tumor resection in reasonable ranges, by taking into account the anatomic and physiological availability, followed by chemo- and radiotherapy.

MATERIALS: the long-term results of treatment were analyzed in 80 patients with oligoglial tumors (oligodendrogliomas and oligoastrocytomas in 31 and 49 patients, respectively) treated at the A.L.

RESULTS: After complex therapy, the mean survival was 80.6 months in patients with oligodendrogliomas, 63.3 months in those with anaplastic oligoastrocytomas, and 42 months in those with anaplastic oligodendrogliomas.

[MeSH-major] Astrocytoma / therapy. Brain Neoplasms / therapy. Oligodendroglioma / therapy

[MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiation Dosage

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18720725.001).

[ISSN] 0042-8817

[Journal-full-title] Zhurnal voprosy neĭrokhirurgii imeni N. N. Burdenko

[ISO-abbreviation] Zh Vopr Neirokhir Im N N Burdenko

[Language] rus

[Publication-type] English Abstract; Journal Article

[Publication-country] Russia (Federation)

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Role of proton magnetic resonance spectroscopy in differentiating oligodendrogliomas from astrocytomas.

BACKGROUND AND PURPOSE: Preoperative differentiation of astrocytomas from oligodendrogliomas is clinically important, as oligodendrogliomas are more sensitive to chemotherapy.

The purpose of this study was to assess the role of proton magnetic resonance spectroscopy in distinguishing astrocytomas from oligodendrogliomas.

METHODS: Forty-six patients [astrocytomas (n= 17) and oligodendrogliomas (n= 29)] underwent magnetic resonance imaging and multi voxel proton magnetic resonance spectroscopic imaging before treatment.

The average metabolite/Cr ratios from these voxels were then compared between astrocytomas and oligodendrogliomas.

RESULTS: A significant difference in mI/Cr was observed between astrocytomas and oligodendrogliomas (.50 +/- .18 vs. 0.66 +/- 0.20, P < .05).

Using a threshold value of .56 for mI/Cr ratio, it was possible to differentiate oligodendrogliomas from astrocytomas with a sensitivity of 72.4% and specificity of 76.4%.

CONCLUSION: These results suggest that mI/Cr might aid in distinguishing oligodendrogliomas from astrocytomas.

[MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Magnetic Resonance Spectroscopy / methods. Oligodendroglioma / diagnosis. Protons

[MeSH-minor] Adult. Aged. Brain / metabolism. Brain / pathology. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. ROC Curve. Sensitivity and Specificity. Young Adult

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19021846.001).

[ISSN] 1552-6569

[Journal-full-title] Journal of neuroimaging : official journal of the American Society of Neuroimaging

[ISO-abbreviation] J Neuroimaging

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Protons

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Reappraisal of the Sainte-Anne Hospital classification of oligodendrogliomas in view of retrospective studies].

[Transliterated title] Classification des oligodendrogliomes de l'hôpital Sainte-Anne. Mise au point à l'usage des études rétrospectives.

PURPOSE: Definition of homogeneous tumor groups of oligodendrogliomas or oligo-astrocytomas is a basic condition for an adequate evaluation and comparison of the results of treatments in patients from various institutions.

PATIENTS AND METHODS: This study included 251 adult patients in whom a SA grade A or B oligodendroglioma or oligo-astrocytoma was newly diagnosed at our institution from 1984 to 2003.

Routine histological preparations and post-contrast preoperative MRI/CT-scan were simultaneously reviewed in order to assess the impact on survival of the following features: presence or absence of a polymorphous or gemistocytic astrocytic component, of necrosis and of contrast enhancement (CH); endothelial hyperplasia (EH) assessed as absent, present minor (HE+) or (HE++) when conform to the threshold of HE defined in the SA grading system of oligodendrogliomas.

RESULTS: 70.1% of the tumors were classified as "pure" oligodendroglioma, 19.5% as "polymorphous oligo-astroastrocytoma" and 10.3% as "gemistocytic oligo-astrocytoma".

In grade A, or B tumors, the presence of a polymorphous or a gemistocytic component had no significant influence on survival; however respectively 53% and 65% of these tumours versus 32% of "pure" oligodendrogliomas were grade B at the time of diagnosis.

After regrouping of the histological subtypes and of the tumors with HE+ or absent, the series included 153 oligodendrogliomas grade A and 98 grade B.

Survival in patients with grade A versus grade B tumors was respectively 142 versus 52 months (p<0.0001).

In grade B tumors, necrosis had no significant influence on survival.

On post contrast MRI done in 235 patients, only 7 tumors (3%) were grade A/B (EH++ but no CH).

CONCLUSIONS: From these results and our previous observation that, according to the SA classification of gliomas, only oligodendrogliomas or oligo-astrocytomas may not show CE, we propose that for retrospective studies:.

1) tumors diagnosed according to the Ste-Anne classification as oligodendroglioma or oligo-astrocytoma be regrouped in a unique category, 2) independent of their histological type and grade according to the WHO, gliomas that do not show CE be regrouped with SA oligodendrogliomas grade A, 3) concerning gliomas that show CE on MRI: oligodendrogliomas or oligo-astrocytomas WHO grade II or III, as well as WHO secondary glioblastomas or glioblastomas with an oligodendroglial component, be regrouped with SA oligodendrogliomas grade B; however tumors that show ring-like CE surrounding large foci of necrosis and finger-like "peritumoral" edema should be excluded or analysed separately.

[MeSH-major] Brain / pathology. Brain / radiography. Brain Neoplasms / classification. Glioma / classification. Oligodendroglioma / classification

[MeSH-minor] Adult. France. Hospitals. Humans. Magnetic Resonance Imaging. Neoplasm Staging. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16292168.001).

[ISSN] 0028-3770

[Journal-full-title] Neuro-Chirurgie

[ISO-abbreviation] Neurochirurgie

[Language] fre

[Publication-type] English Abstract; Journal Article

[Publication-country] France

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Oligodendrogliomas lacking O6-methylguanine-DNA-methyltransferase expression.

We evaluated the immunohistochemical MGMT expression in 28 consecutive oligodendroglial tumors (21 oligodendrogliomas, 5 mixed oligoastrocytomas, and 2 glioblastomas with prominent oligodendroglial features; 13 treated with CCNU) and compared it with that of 13 glioblastomas.

Twenty-six (93%) oligodendroglial tumors were MGMT-negative, 2 (7%) were MGMT-positive.

Twelve (92%) patients treated with CCNU had MGMT-negative lesions and their median survival was 73 months; 1 patient had an MGMT-positive oligodendroglioma and is alive at 28 months.

The lower MGMT expression in oligodendroglial tumors compared to glioblastomas (P < 0.05), which have different chemosensitivity, suggests a possible role of MGMT in the determination of chemoresistance.

Nevertheless, the heterogeneous outcome of our MGMT-negative oligodendroglial tumors treated with CCNU, indicates that MGMT expression alone is insufficient to predict the response to alkylating drugs, presumably because of the numerous mechanisms involved.

[MeSH-major] Antineoplastic Agents / pharmacology. Brain Neoplasms / genetics. DNA Repair. Gene Expression Profiling. Glioblastoma / genetics. Nitrosourea Compounds / pharmacology. O(6)-Methylguanine-DNA Methyltransferase / analysis. O(6)-Methylguanine-DNA Methyltransferase / genetics. Oligodendroglioma / genetics

[MeSH-minor] Adult. Aged. Drug Resistance, Neoplasm. Female. Humans. Immunohistochemistry. Male. Middle Aged. Survival Analysis

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16038527.001).

[ISSN] 1120-009X

[Journal-full-title] Journal of chemotherapy (Florence, Italy)

[ISO-abbreviation] J Chemother

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] Italy

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Nitrosourea Compounds; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Prognostic and survival-related factors in patients with well-differentiated oligodendrogliomas.

Oligodendrogliomas are brain tumors with unpredictable biological and clinical behavior.

The present study reviews 50 patients with well-differentiated (WHO grade II) oligodendrogliomas, located in the cerebral hemispheres and operated upon between 1980 and 1998.

Prognostic factors studied include patient's age and sex, tumor location and extent, preoperative KPS, and extent of the surgical resection.

The long-term outcome and survival are not significantly correlated with the patient's age and sex, tumor location and extent, preoperative KPS and procedure for resection.

The presented data suggest that low proliferation indices and negative GF expression are associated with longer survival in well-differentiated oligodendrogliomas.

[MeSH-major] Brain Neoplasms / mortality. Oligodendroglioma / mortality

[MeSH-minor] Adolescent. Adult. Aged. Aging. Antineoplastic Agents / therapeutic use. Biomarkers, Tumor. Cell Proliferation. Child. Combined Modality Therapy. Female. Humans. Intercellular Signaling Peptides and Proteins / analysis. Ki-67 Antigen / analysis. Male. Middle Aged. Neurosurgical Procedures. Prognosis. Proliferating Cell Nuclear Antigen / analysis. Treatment Outcome

MedlinePlus Health Information. consumer health - Brain Tumors.

MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17106834.001).

[ISSN] 0044-4251

[Journal-full-title] Zentralblatt für Neurochirurgie

[ISO-abbreviation] Zentralbl. Neurochir.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Germany

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Intercellular Signaling Peptides and Proteins; 0 / Ki-67 Antigen; 0 / Proliferating Cell Nuclear Antigen

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Cerebral oligodendrogliomas in adults and children. Current data and perspectives.

Cerebral oligodendrogliomas represent more than 30% of glial tumors in adults.

Mean age at diagnosis is 41 for grade A and 45(1/2) for grade B, epilepsy being the main revealing symptom (91.5% of A, 76% of B).

Survival at 5, 10 and 15 years is respectively 75.5%, 51% and 22.4% for grade A (median: 136 months), and 45.2%, 31.3% and 0% for grade B (median: 52 months).

In children, they represent less than 2.5% of cerebral tumors and include 23% grade A and 77% grade B (48.5% WHO grade II and 51.5% WHO grade III).

The main differential diagnosis of grade A oligo is dysembryoplastic neuroepithelial tumors (DNT).

Inversely, thalamic locations, most often grade B, generally present with a motor deficit; complete removal can be achieved in only 15%.

[MeSH-major] Brain Neoplasms / pathology. Oligodendroglioma / pathology

[MeSH-minor] Adult. Child. Chromosome Deletion. Chromosomes, Human, Pair 1 / genetics. Diagnosis, Differential. Humans. Magnetic Resonance Spectroscopy. Middle Aged. Neoplasm Staging

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16292183.001).

[ISSN] 0028-3770

[Journal-full-title] Neuro-Chirurgie

[ISO-abbreviation] Neurochirurgie

[Language] eng; fre

[Publication-type] Journal Article

[Publication-country] France

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Chromosomal imbalances detected by array comparative genomic hybridization in human oligodendrogliomas and mixed oligoastrocytomas.

Loss of heterozygosity and fluorescence in situ hybridization (FISH) studies have shown that deletions of 1p and 19q are highly prevalent in oligodendroglioma.

In this study, we used array-based comparative genomic hybridization (CGHa) of mapped BAC DNA to screen for such alterations in 31 oligodendrogliomas (20 grade II, 9 grade III, and 2 grade IV) and 4 mixed oligoastrocytomas (1 grade I, 1 grade II, and 2 grade IV).

In addition, 8q gain in the oligodendrogliomas was strongly associated with poor outcome (P = 0.002).

Also associated with poor disease outcome were alterations that had low prevalence in the pure oligodendrogliomas, including loss of 3q, 9q, and 12q and gain of 1p, 8p, and 10q.

In summary, in oligodendrogliomas, CGHa was able to detect novel small alterations in chromosomal dosage that had not been previously detected by other methods.

In addition, our findings support the hypotheses that oligodendroglioma can be classified into several groups by CGHa analysis and that specific alterations in genetic dosage may have biologic or clinical significance.

[MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Nucleic Acid Hybridization / genetics. Oligodendroglioma / genetics

[MeSH-minor] Adult. Child. Chromosome Mapping. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Female. Humans. Male. Middle Aged. Oligonucleotide Array Sequence Analysis

MedlinePlus Health Information. consumer health - Brain Tumors.

MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15472895.001).

[ISSN] 1045-2257

[Journal-full-title] Genes, chromosomes & cancer

[ISO-abbreviation] Genes Chromosomes Cancer

[Language] eng

[Grant] United States / NCI NIH HHS / CA / CA85799

[Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Prognostic value of CXCL12 expression in 40 low-grade oligodendrogliomas and oligoastrocytomas.

Both clinical and biological features have been reported as prognostic factors in low-grade gliomas.

Among these, histotype, tumor size, enhancement, age and genetic pattern.

Microvessel density (MVD) has been correlated to clinical outcome in astrocytomas, but its impact in oligodendrogliomas and mixed tumors is not sure.

The pro-angiogenic chemokine stromal cell-derived factor (SDF-1/CXCL12) and its receptor CXC chemokine receptor 4 (CXCR4) have been described in low-grade gliomas, with a correlation between CXCL12 expression and shorter time to progression (TTP).

[MeSH-major] Astrocytoma / blood supply. Astrocytoma / diagnosis. Brain Neoplasms / blood supply. Brain Neoplasms / diagnosis. Chemokines, CXC / analysis. Neovascularization, Pathologic / diagnosis. Oligodendroglioma / blood supply. Oligodendroglioma / diagnosis

[MeSH-minor] Adolescent. Adult. Aged. Capillaries / pathology. Chemokine CXCL12. Female. Humans. Intermediate Filament Proteins / analysis. Male. Middle Aged. Nerve Tissue Proteins / analysis. Nestin. Prognosis. Proto-Oncogene Proteins c-sis / analysis. Receptor, Platelet-Derived Growth Factor beta / analysis. Receptors, CXCR4 / analysis

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Cancer Biol Ther. 2006 Aug;5(8):1039-41 [16931903.001]

(PMID = 16760646.001).

[ISSN] 1538-4047

[Journal-full-title] Cancer biology & therapy

[ISO-abbreviation] Cancer Biol. Ther.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / CXCL12 protein, human; 0 / Chemokine CXCL12; 0 / Chemokines, CXC; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; 0 / Proto-Oncogene Proteins c-sis; 0 / Receptors, CXCR4; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Is the 1p/19q deletion a diagnostic marker of oligodendrogliomas?

Combined loss of chromosome arms 1p and 19q (denoted as 1p-/19q-) has proven to be a powerful predictor of chemotherapeutic response and survival in oligodendrogliomas.

We undertook retrospective and prospective studies of brain tumor patients originally diagnosed as oligodendrogliomas or oligoastrocytomas patients followed at our institution using molecular genetic techniques.

All of the pure oligodendrogliomas (n=7) harbored 1p-/19q-.

In light of previous findings, the 1p-/19q- combination appears to be an objective diagnosis marker of classic oligodendrogliomas, one that can be used, in combination with histological examination, to improve the diagnosis of oligodendroglioma.

[MeSH-major] Chromosome Deletion. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Oligodendroglioma / diagnosis. Oligodendroglioma / genetics

[MeSH-minor] Adolescent. Adult. Aged. Female. Humans. In Situ Hybridization, Fluorescence. Kaplan-Meier Estimate. Loss of Heterozygosity. Male. Microsatellite Repeats / genetics. Middle Aged. Polymerase Chain Reaction. Sensitivity and Specificity. Young Adult

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19737649.001).

[ISSN] 1873-4456

[Journal-full-title] Cancer genetics and cytogenetics

[ISO-abbreviation] Cancer Genet. Cytogenet.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Proliferation (MIB-1 expression) in oligodendrogliomas: assessment of quantitative methods and prognostic significance.

The authors assessed three techniques for quantitating MIB-1 (expression in oligodendrogliomas, correlating results with mitotic activity and prognosis.

Formalin-fixed, paraffin-embedded sections of 38 oligodendrogliomas were immunostained using monoclonal MIB-l.

MIB-1 expression and mitotic count were correlated with overall survival and recurrence (disease-free survival), defined clinically and radiographically as new tumor growth.

The authors show a significant correlation between MIB-1 PI using the visual method and recurrence in patients with oligodendrogliomas.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16540741.001).

[ISSN] 1541-2016

[Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM

[ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.

[Language] ENG

[Publication-type] Comparative Study; Evaluation Studies; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Ki-67 Antigen

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Proposal of a scoring scale as a survival predictor in intracranial oligodendrogliomas.

INTRODUCTION: Histological, clinical and radiological features, and molecular genetic analysis are among the factors that have been considered in defining the prognosis of oligodendrogliomas (OD), but they have yielded conflicting results.

[MeSH-major] Brain Neoplasms / classification. Brain Neoplasms / pathology. Oligodendroglioma / classification. Oligodendroglioma / pathology

[MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Chromosomes, Human, Pair 1 / genetics. Diagnosis-Related Groups. Female. Gene Deletion. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Multivariate Analysis. Necrosis. Neoplasm Staging. Predictive Value of Tests. Prognosis. Proportional Hazards Models. Statistics, Nonparametric. Survival Analysis

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Surg Neurol. 2002 Aug;58(2):111-7; discussion 117 [12453646.001]

[Cites] Am J Pathol. 1999 Aug;155(2):375-86 [10433931.001]

[Cites] Neuro Oncol. 2003 Apr;5(2):128-38 [12672285.001]

[Cites] J Neurooncol. 2001 Oct;55(1):45-50 [11804282.001]

[Cites] Acta Neurochir (Wien). 2001 Dec;143(12):1195-203 [11810382.001]

[Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]

[Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]

[Cites] Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1405-9 [12459363.001]

[Cites] J Neurosurg. 1992 Mar;76(3):428-34 [1738022.001]

[Cites] Acta Neurol Scand. 2002 Jul;106(1):19-23 [12067323.001]

[Cites] Neurosurgery. 1999 Dec;45(6):1279-91; discussion 191 [10598694.001]

[Cites] J Neurooncol. 1997 Aug;34(1):61-78 [9210053.001]

[Cites] J Neurooncol. 1997 Aug;34(1):37-59 [9210052.001]

[Cites] Cancer Res. 2001 Sep 15;61(18):6713-5 [11559541.001]

[Cites] Best Pract Res Clin Haematol. 2001 Sep;14(3):645-69 [11640874.001]

[Cites] Neurosurgery. 1994 Dec;35(6):1018-34; discussion 1034-5 [7885546.001]

[Cites] Oncogene. 1999 Jul 15;18(28):4144-52 [10435596.001]

[Cites] Ann Clin Lab Sci. 1994 Mar-Apr;24(2):153-63 [8203823.001]

[Cites] Cancer. 1988 Jun 1;61(11):2251-9 [3365653.001]

[Cites] J Neuropathol Exp Neurol. 1992 Mar;51(2):127-32 [1538237.001]

[Cites] Am J Pathol. 2001 Apr;158(4):1253-62 [11290543.001]

[Cites] J Neuropathol Exp Neurol. 2003 Feb;62(2):111-26 [12578221.001]

[Cites] Clin Cancer Res. 2001 Apr;7(4):839-45 [11309331.001]

[Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]

[Cites] J Neurooncol. 2004 Jul;68(3):263-74 [15332331.001]

[Cites] Arch Neurol. 1999 Apr;56(4):434-6 [10199331.001]

[Cites] Neurosurgery. 1988 May;22(5):886-91 [3380278.001]

[Cites] Cancer Res. 2001 Mar 1;61(5):1825-9 [11280731.001]

[Cites] J Neurosurg. 2002 Mar;96(3):559-64 [11892633.001]

[Cites] Cancer. 1997 Apr 1;79(7):1381-93 [9083161.001]

[Cites] J Neurosurg. 1988 May;68(5):684-8 [3357029.001]

[Cites] J Neurooncol. 1999 Jun;43(2):179-85 [10533731.001]

[Cites] Radiology. 1993 Feb;186(2):569-72 [8421767.001]

[Cites] Surg Neurol. 2000 Sep;54(3):229-34; discussion 234 [11118569.001]

[Cites] J Neurooncol. 2000 May;48(1):13-9 [11026692.001]

[Cites] Ann Diagn Pathol. 2000 Aug;4(4):218-27 [10982299.001]

[Cites] Ann Diagn Pathol. 2003 Feb;7(1):9-13 [12616468.001]

[Cites] J Neurosurg. 1985 Dec;63(6):881-9 [4056902.001]

[Cites] Acta Neuropathol. 1998 May;95(5):493-504 [9600596.001]

[Cites] J Neurosurg. 1987 Aug;67(2):224-30 [3598683.001]

[Cites] Cancer Res. 2003 Apr 1;63(7):1602-7 [12670911.001]

[Cites] Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1254-64 [12128127.001]

[Cites] Cancer. 1983 Dec 1;52(11):2107-14 [6627218.001]

(PMID = 16821091.001).

[ISSN] 0167-594X

[Journal-full-title] Journal of neuro-oncology

[ISO-abbreviation] J. Neurooncol.

[Language] eng

[Publication-type] Evaluation Studies; Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas.

Despite the richness of TCGA GBM data, the absence of lower grade gliomas in this data set prevents analysis genes related to progression and the uncovering of predictive signatures.

A complementary dataset exists in the form of the NCI Repository for Molecular Brain Neoplasia Data (Rembrandt), which contains molecular and clinical data for diffuse gliomas across the full spectrum of histologic class and grade.

We demonstrate that the proneural signature predicts improved clinical outcome among 176 Rembrandt gliomas that includes all histologies and grades, including GBMs (log rank test p = 1.16e-6), but also among 75 grade II and grade III samples (p  =  2.65e-4).

This gene expression signature was enriched in tumors with oligodendroglioma histology and also predicted improved survival in this tumor type (n =  43, p  =  1.25e-4).

Thus, expression signatures identified in the TCGA analysis of GBMs also have intrinsic prognostic value for lower grade oligodendrogliomas, and likely represent important differences in tumor biology with implications for treatment and therapy.

Integrated DNA and RNA analysis of low-grade and high-grade proneural gliomas identified increased expression and gene amplification of several genes including GLIS3, TGFB2, TNC, AURKA, and VEGFA in proneural GBMs, with corresponding loss of DLL3 and HEY2.

This demonstrates that the expression signatures identified in the TCGA analysis of GBMs also have intrinsic prognostic value for low-grade oligodendrogliomas, and likely represent important differences in tumor biology with implications for treatment and therapy.

MedlinePlus Health Information. consumer health - Brain Tumors.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cancer Res. 2006 Dec 15;66(24):11771-80 [17178873.001]

[Cites] J Neuropathol Exp Neurol. 2006 Jun;65(6):529-39 [16783163.001]

[Cites] Biochem Biophys Res Commun. 2007 Mar 9;354(2):567-73 [17250806.001]

[Cites] Bioinformatics. 2007 Dec 1;23(23):3251-3 [17644558.001]

[Cites] Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):20007-12 [18077431.001]

[Cites] BMC Genomics. 2007;8:461 [18088408.001]

[Cites] Nature. 2008 Oct 23;455(7216):1061-8 [18772890.001]

[Cites] Mol Cancer Res. 2009 Feb;7(2):157-67 [19208739.001]

[Cites] Cancer Res. 2009 Mar 1;69(5):2091-9 [19244127.001]

[Cites] Oncogene. 2009 Oct 1;28(39):3468-76 [19617900.001]

[Cites] Cancer Cell. 2010 Jan 19;17(1):98-110 [20129251.001]

[Cites] Cancer Cell. 2010 May 18;17(5):510-22 [20399149.001]

[Cites] Lab Invest. 2000 Jun;80(6):837-49 [10879735.001]

[Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6567-72 [12011421.001]

[Cites] J Biol Chem. 2002 Aug 16;277(33):29399-405 [12050162.001]

[Cites] Genome Biol. 2003;4(5):P3 [12734009.001]

[Cites] Biostatistics. 2003 Apr;4(2):249-64 [12925520.001]

[Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]

[Cites] EMBO J. 1988 Oct;7(10):2977-82 [2460335.001]

[Cites] Am J Physiol. 1995 Feb;268(2 Pt 1):L173-80 [7532367.001]

[Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]

[Cites] Science. 1999 Jun 18;284(5422):1994-8 [10373119.001]

[Cites] Am J Roentgenol Radium Ther Nucl Med. 1962 Mar;87:473-9 [13919885.001]

[Cites] Bioinformatics. 2004 Nov 22;20(17):3246-8 [15180930.001]

[Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]

[Cites] Bioinformatics. 2006 Jan 1;22(1):122-3 [16269418.001]

[Cites] Blood. 2006 Feb 1;107(3):931-9 [16219802.001]

[Cites] Cancer Cell. 2006 Mar;9(3):157-73 [16530701.001]

[Cites] Nat Genet. 2006 May;38(5):500-1 [16642009.001]

[Cites] Curr Biol. 2007 Jan 23;17(2):165-72 [17196391.001]

(PMID = 20838435.001).

[ISSN] 1932-6203

[Journal-full-title] PloS one

[ISO-abbreviation] PLoS ONE

[Language] ENG

[Grant] United States / PHS HHS / / S09-094; United States / NIBIB NIH HHS / EB / P20 EB000591; United States / NCATS NIH HHS / TR / UL1 TR000454; United States / NCRR NIH HHS / RR / UL1 RR025008; United States / NLM NIH HHS / LM / R01 LM011119

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor

[Other-IDs] NLM/ PMC2933229

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Metastatic oligodendrogliomas: a review of the literature and case report.

Oligodendroglioma cells are detectable in the cerebro-spinal fluid in up to 14% of patients [10] and cerebellar and/or spinal cord involvement is a well known phenomenon [3].

Distant spread of oligodendroglioma is exceptional, probably due to the presence of the blood-brain barrier, the absence of lymphatic vessels and the short survival of patients.

This review was performed using NCBI-PubMed and "oligodendroglioma, oligodendrogliomas, metastatic, metastasis, metastases, extraneural", in different combinations, as key words and reviewing the bibliography of the consequent selected articles.

New therapeutic approaches are prolonging the overall survival of patients with primitive brain tumours and in particular of those with high grade oligodendroglioma which is a chemo-sensitive disease.

[MeSH-major] Brain Neoplasms / pathology. Liver Neoplasms / secondary. Occipital Lobe. Oligodendroglioma / secondary. Parietal Lobe

[MeSH-minor] Adult. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Acta Neurochir (Wien). 2009 Aug;151(8):987 [19424658.001]

(PMID = 18548193.001).

[ISSN] 0942-0940

[Journal-full-title] Acta neurochirurgica

[ISO-abbreviation] Acta Neurochir (Wien)

[Language] eng

[Publication-type] Case Reports; Journal Article; Review

[Publication-country] Austria

[Number-of-references] 29

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Does radiosurgery have a role in the management of oligodendrogliomas?

OBJECT: In this study the authors evaluated the role of stereotactic radiosurgery (SRS) in the management of progressive or newly diagnosed small-volume oligodendrogliomas.

Tumor control, survival, and complications were assessed in patients with oligodendroglioma who underwent Gamma Knife radiosurgery as a primary or adjuvant procedure.

METHODS: The authors retrospectively reviewed 30 patients with oligodendroglioma (12 Grade II and 18 Grade III) who underwent SRS between 1992 and June 2006 at the University of Pittsburgh.

Twenty-four patients had previously undergone resection of the tumor, whereas tumors in 6 were diagnosed based on biopsy findings.

The SRS was performed in 25 patients who had imaging-defined tumor progression despite prior fractionated radiation (22 patients) and/or chemotherapy (20 patients).

The overall survival rates from diagnosis to 5 and 10 years were 90.9 and 68.2%, respectively, for Grade II and 52.1% at 5 years and 26.1% at 10 years for Grade III.

Factors associated with an improved progression-free survival included lower tumor grade and smaller tumor volume.

CONCLUSIONS: The SRS modality is a minimally invasive additional option for patients with residual or recurrent oligodendrogliomas.

It may also be considered as an alternative to initial resection in small-volume tumors located in the cortical brain region.

[MeSH-major] Brain Neoplasms / surgery. Oligodendroglioma / surgery. Radiosurgery

[MeSH-minor] Adolescent. Adult. Child. Female. Humans. Loss of Heterozygosity. Male. Middle Aged. Retrospective Studies

MedlinePlus Health Information. consumer health - Brain Tumors.

MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18950268.001).

[ISSN] 0022-3085

[Journal-full-title] Journal of neurosurgery

[ISO-abbreviation] J. Neurosurg.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Fluid-attenuated inversion-recovery MR imaging in assessment of intracranial oligodendrogliomas.

This retrospective study consisted of 17 consecutive patients with oligodendrogliomas.

We qualitatively and quantitatively assessed the diagnostic value of fluid-attenuated inversion-recovery (FLAIR) images compared with T2-weighted fast spin-echo (FSE) images for evaluating intracranial oligodendrogliomas.

Qualitative evaluations of signal intensity, tumor conspicuity, definition of tumor margin, distinction between solid and cystic-like parts within tumor, and calcification were performed.

Quantitative criteria comparing FLAIR to T2-weighted FSE images included tumor-to-background contrast and contrast-to-noise ratio (CNR) and tumor-to-cerebrospinal fluid (CSF) contrast and CNR.

Our results demonstrate that the FLAIR sequence can replace the T2-weighted FSE sequence for evaluating oligodendrogliomas.

[MeSH-major] Brain Neoplasms / diagnosis. Magnetic Resonance Imaging / methods. Oligodendroglioma / diagnosis

[MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Image Enhancement. Male. Middle Aged. Retrospective Studies. United States

MedlinePlus Health Information. consumer health - Brain Tumors.

MedlinePlus Health Information. consumer health - MRI Scans.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15890255.001).

[ISSN] 0895-6111

[Journal-full-title] Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society

[ISO-abbreviation] Comput Med Imaging Graph

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Gene expression profiles associated with treatment response in oligodendrogliomas.

Oligodendrogliomas are a specific subtype of brain tumor of which the majority responds favorably to chemotherapy.

In this study, we made use of expression profiling to identify chemosensitive oligodendroglial tumors.

Because transcripts associated with chemotherapeutic response were identified independent of common chromosomal aberrations, expression profiling may be used as an alternative approach to the tumors' 1p status to identify chemosensitive oligodendroglial tumors.

The observation that many genes are differentially expressed between long and short survivors indicates that the genetic background of the tumor is an important factor in determining the prognosis of the patient.

Our study is the first to correlate gene expression with chromosomal aberrations and clinical performance (response to treatment and survival) in oligodendrogliomas.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Loss of Heterozygosity. Oligodendroglioma / genetics

[MeSH-minor] Adult. Aged. Aged, 80 and over. Brain Neoplasms / drug therapy. Brain Neoplasms / genetics. Chromosome Aberrations. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. DNA, Neoplasm / genetics. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Prognosis. Survival Rate. Treatment Outcome

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16357140.001).

[ISSN] 0008-5472

[Journal-full-title] Cancer research

[ISO-abbreviation] Cancer Res.

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / DNA, Neoplasm

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Dysembryoplastic neuroepithelial tumor (DNT)-like oligodendrogliomas or Dnts evolving into oligodendrogliomas: two illustrative cases.

A review of dysembryoplastic neuroepithelial tumors (DNTs) in 14 patients over a 12-year period revealed four patients re-operated because of changes on magnetic resonance imaging (MRI) suggesting tumor recurrence or progression.

In the fourth patient, persistent DNT was surrounded by WHO grade 2 oligoastrocytoma.

In one of the other 10 patients, WHO grade 2 oligodendroglioma was present in white matter deep to and completely separate from a cortically based DNT.

Fluorescence in situ hybridization showed codeletion of 1p and 19q in both the DNT and oligodendroglioma and oligoastrocytoma components.

Deletions were not identified in any other tumor.

These two unusual tumors also raise the possibility that rare DNTs may evolve into oligodendroglioma or oligoastrocytoma.

[MeSH-major] Neoplasms, Multiple Primary / pathology. Neoplasms, Neuroepithelial / pathology. Oligodendroglioma / pathology

[MeSH-minor] Adult. Astrocytoma / genetics. Astrocytoma / pathology. Astrocytoma / surgery. Chromosome Deletion. Electroencephalography. Female. Humans. In Situ Hybridization, Fluorescence. Magnetic Resonance Imaging. Middle Aged. Tomography, X-Ray Computed

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17899685.001).

[ISSN] 0919-6544

[Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology

[ISO-abbreviation] Neuropathology

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Australia

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Clinical significance of astrocyte elevated gene-1 expression in human oligodendrogliomas.

OBJECTIVE: To investigate the expression of astrocyte elevated gene-1 (AEG-1) in human oligodendrogliomas and the association between AEG-1 expression and progression of oligodendrogliomas.

METHODS: The expression of AEG-1 in normal human oligodendroglial cells, oligodendroglioma cell line, and four pairs of matched oligodendroglioma tissues and their adjacent normal brain tissues was detected by quantitative RT-PCR and western blotting.

In addition, AEG-1 protein expression was examined in 75 cases of histologically characterized oligodendrogliomas by immunohistochemistry.

RESULTS: Western blotting and RT-PCR showed that AEG-1 mRNA and protein were elevated in the oligodendroglioma cell line and significantly upregulated in primary oligodendrogliomas compared with the adjacent non-cancerous brain tissues.

Immunohistochemical analysis showed that 51 of 75 (68.0%) paraffin-embedded archival oligodendroglioma samples exhibited high expression of AEG-1.

Statistical analysis suggested that upregulation of AEG-1 was significantly correlated with the histological grade of oligodendroglioma (p=0.000) and that patients with high AEG-1 level exhibited shorter survival time (p=0.000).

Multivariate analysis revealed that AEG-1 upregulation might be an independent prognostic indicator for the survival of patients with oligodendroglioma.

CONCLUSIONS: AEG-1 might represent a novel, useful diagnostic and prognostic marker for oligodendroglioma and play a role during the development and progression of the disease.

[MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Cell Adhesion Molecules / genetics. Oligodendroglioma / genetics. Oligodendroglioma / pathology

[MeSH-minor] Adult. Blotting, Western. DNA Primers / genetics. Female. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Male. Middle Aged. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright 2010 Elsevier B.V. All rights reserved.

(PMID = 20236756.001).

[ISSN] 1872-6968

[Journal-full-title] Clinical neurology and neurosurgery

[ISO-abbreviation] Clin Neurol Neurosurg

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Netherlands

[Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / DNA Primers; 0 / Ki-67 Antigen; 0 / MTDH protein, human; 0 / RNA, Messenger

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Chromosome 1p/19q status combined with expression of p53 protein improves the diagnostic and prognostic evaluation of oligodendrogliomas.

BACKGROUND: Our previous study confirmed that oligodendrogliomas had higher frequency of chromosome 1p/19q deletion.

In order to improve the diagnostic criteria and to predict the prognosis of oligodendroglioma patients, the status of chromosome 1p/19q deletion, the methylation of O(6)-methylguanine-DNA methyltransferase (MGMT), and the expression of p53 protein were evaluated and investigated in relation to patients' outcomes.

RESULTS: Both oligodendrogliomas and astrocytic gliomas exhibited frequent methylation of MGMT.

The expression of p53 protein was more frequently observed in patients without a 1p or 19q deletion in anaplastic oligodendrogliomas (P = 0.032, 0.025).

In low-grade oligodendrogliomas, methylation of MGMT was more frequent in patients with 1p/19q deletion than in patients with 1p/19q intact (P = 0.038).

Patients with oligodendrogliomas with 1p/19q loss of heterozygosity and p53-negative showed a longer progression-free survival.

CONCLUSION: Detection of chromosome 1p/19q status combined with p53 protein immunohistochemistry might be beneficial to improve the pathological diagnosis and to determine the prognosis of patients with oligodendrogliomas.

[MeSH-major] Brain Neoplasms / genetics. Chromosome Deletion. Chromosomes, Human, Pair 19. Oligodendroglioma / genetics. Tumor Suppressor Protein p53 / analysis

[MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / genetics. Child. Chromosomes, Human, Pair 1. DNA Methylation. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Disease-Free Survival. Female. Gene Expression Regulation, Neoplastic. Humans. Loss of Heterozygosity. Male. Middle Aged. Prognosis. Tumor Suppressor Proteins / genetics

MedlinePlus Health Information. consumer health - Brain Tumors.

MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 22166632.001).

[ISSN] 0366-6999

[Journal-full-title] Chinese medical journal

[ISO-abbreviation] Chin. Med. J.

[Language] eng

[Publication-type] Journal Article

[Publication-country] China

[Chemical-registry-number] 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes; Chromosome 1, monosomy 1p

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Gene amplification is a poor prognostic factor in anaplastic oligodendrogliomas.

Prognostic-genomic correlations testing simultaneously all these amplified genes have never been conducted in anaplastic oligodendrogliomas.

A set of 38 genes that have been reported to be amplified in gliomas and investigated as the main targets of amplicons were studied in a series of 52 anaplastic oligodendrogliomas using bacterial artificial chromosome-array based comparative genomic hybridization and quantitative polymerase chain reaction.

Among the 38 target genes, 15 were found to be amplified in at least one tumor.

Overall, 27% of anaplastic oligodendrogliomas exhibited at least one gene amplification.

The most frequently amplified genes were epidermal growth factor receptor (EGFR) and cyclin-dependent kinase 4/sarcoma amplified sequence (CDK4/SAS) in 17% and 8% of anaplastic oligodendrogliomas, respectively.

In uni- and multivariate analyses, gene amplification was a negative prognostic factor for progression-free survival and overall survival in anaplastic oligodendrogliomas, providing complementary information to the classic prognostic factors identified in anaplastic oligodendrogliomas (extent of surgery, KPS, and chromosome arms 1p/19q status).

[MeSH-major] Brain Neoplasms / genetics. Gene Amplification. Oligodendroglioma / genetics

[MeSH-minor] Adult. Aged. Aged, 80 and over. Chromosomes, Artificial, Bacterial. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Nucleic Acid Hybridization. Prognosis. Reverse Transcriptase Polymerase Chain Reaction

MedlinePlus Health Information. consumer health - Brain Tumors.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Glia. 1995 Nov;15(3):289-96 [8586464.001]

[Cites] Genes Chromosomes Cancer. 1995 Jan;12(1):63-5 [7534113.001]

[Cites] Cancer Res. 1996 Nov 15;56(22):5141-5 [8912848.001]

[Cites] Cancer Res. 1997 Apr 1;57(7):1250-4 [9102208.001]

[Cites] Hum Mol Genet. 1997 Oct;6(11):1817-22 [9302258.001]

[Cites] Hum Genet. 1997 Dec;101(2):190-7 [9402967.001]

[Cites] Clin Cancer Res. 1998 Jan;4(1):215-22 [9516974.001]

[Cites] Oncogene. 1998 Jun 11;16(23):2997-3002 [9662332.001]

[Cites] Int J Oncol. 1998 Oct;13(4):717-24 [9735401.001]

[Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]

[Cites] Brain Pathol. 1999 Jul;9(3):435-42; discussion 432-3 [10416984.001]

[Cites] Cancer. 2004 Nov 15;101(10):2318-26 [15470710.001]

[Cites] Am J Clin Pathol. 2005 Jun;123(6):900-6 [15899783.001]

[Cites] Genes Chromosomes Cancer. 2005 Sep;44(1):85-96 [15940691.001]

[Cites] Neuropathol Appl Neurobiol. 2005 Oct;31(5):486-90 [16150119.001]

[Cites] Diagn Mol Pathol. 2005 Dec;14(4):224-9 [16319692.001]

[Cites] Cancer Lett. 2006 Jan 28;232(1):79-89 [16288831.001]

[Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]

[Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]

[Cites] Nucleic Acids Res. 2006 Jul 1;34(Web Server issue):W477-81 [16845053.001]

[Cites] J Neuropathol Exp Neurol. 2006 Oct;65(10):988-94 [17021403.001]

[Cites] Mol Cancer. 2006;5:39 [17002787.001]

[Cites] Cancer Res. 2006 Oct 15;66(20):9852-61 [17047046.001]

[Cites] J Clin Oncol. 2006 Dec 1;24(34):5419-26 [17135643.001]

[Cites] Mol Cancer Res. 2006 Dec;4(12):927-34 [17189383.001]

[Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]

[Cites] Int J Cancer. 2008 Apr 15;122(8):1778-86 [18076069.001]

[Cites] Genes Chromosomes Cancer. 2005 Jan;42(1):68-77 [15472895.001]

[Cites] Int J Oncol. 2004 Dec;25(6):1789-94 [15547718.001]

[Cites] Acta Neuropathol. 2005 Mar;109(3):294-8 [15627206.001]

[Cites] J Neuropathol Exp Neurol. 2000 Jun;59(6):495-503 [10850862.001]

[Cites] Cancer Res. 2001 Mar 1;61(5):2162-8 [11280781.001]

[Cites] Clin Cancer Res. 2001 Apr;7(4):839-45 [11309331.001]

[Cites] Clin Cancer Res. 2001 Apr;7(4):868-75 [11309335.001]

[Cites] Lab Invest. 2001 May;81(5):717-23 [11351043.001]

[Cites] Br J Cancer. 2001 Aug 17;85(4):518-22 [11506489.001]

[Cites] Glia. 2001 Oct;36(1):1-10 [11571779.001]

[Cites] Int J Oncol. 2002 Jan;20(1):173-6 [11743660.001]

[Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]

[Cites] Int J Cancer. 2003 May 10;104(6):752-7 [12640683.001]

[Cites] Brain Pathol. 2003 Oct;13(4):507-18 [14655756.001]

[Cites] Brain Tumor Pathol. 2003;20(2):59-63 [14756442.001]

[Cites] J Neuropathol Exp Neurol. 2004 Feb;63(2):151-8 [14989601.001]

[Cites] Nat Genet. 2004 Sep;36(9):949-51 [15286789.001]

[Cites] Lancet. 1985 Sep 28;2(8457):718-9 [2863693.001]

[Cites] Proc Natl Acad Sci U S A. 1986 Jan;83(2):470-3 [3001737.001]

[Cites] Hua Xi Yi Ke Da Xue Xue Bao. 1989 Sep;20(3):243-5 [2560457.001]

[Cites] Cancer Commun. 1990;2(6):201-5 [2165797.001]

[Cites] Cancer Res. 1993 Jun 15;53(12):2736-9 [8504413.001]

[Cites] Hum Genet. 1996 Nov;98(5):625-8 [8882887.001]

(PMID = 18544654.001).

[ISSN] 1522-8517

[Journal-full-title] Neuro-oncology

[ISO-abbreviation] Neuro-oncology

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Other-IDs] NLM/ PMC2666226

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Chromosome 1p and 19q evaluation in low-grade oligodendrogliomas: a descriptive study.

Oligodendrogliomas are rare primary brain tumors with variable patient outcomes which are not always adequately accounted for by clinical or pathological variables.

The present study evaluated the prognostic implications of chromosome 1p and 19q status in a set of 23 low grade oligodendrogliomas (OGD II), and correlated the results with patient outcome.

Our results showed that the molecular alterations are associated with age and tumor localization.

Further studies are now ongoing to determine whether this methodological approach could be potentially useful in low grade oligodendrogliomas to better characterize chromosomal alterations of 1p/19q and identify subgroups of patients with a higher risk of disease recurrence.

[MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / genetics. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Oligodendroglioma / diagnosis. Oligodendroglioma / genetics

[MeSH-minor] Adult. Aged. Chromosome Aberrations. Chromosome Deletion. Female. Humans. Loss of Heterozygosity. Male. Middle Aged. Prognosis

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19956913.001).

[ISSN] 1791-244X

[Journal-full-title] International journal of molecular medicine

[ISO-abbreviation] Int. J. Mol. Med.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Greece

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging.

BACKGROUND AND PURPOSE: Histopathologic evaluation remains the reference standard for diagnosis of glioma and classification of histologic subtypes, but is challenged by subjective criteria, tissue sampling error, and lack of specific tumor markers.

The purpose of our study was to investigate dynamic susceptibility contrast-enhanced (DSC) MR imaging characteristics of the two most common subtypes of low-grade infiltrating glioma: astrocytoma and oligodendroglioma.

We hypothesized that tumor blood-volume measurements, derived from DSC MR imaging, would help differentiate the two on the basis of differences in tumor vascularity.

METHODS: We studied 25 consecutive patients with treatment-naive, histopathologically confirmed World Health Organization grade II astrocytoma (n = 11) or oligodendroglioma (n = 14).

RESULTS: The maximum relative CBV (rCBV(max)) in tumor ranged from 0.48 to 1.34 (0.92 +/- 0.27, median +/- SD) in astrocytomas and from 1.29 to 9.24 (3.68 +/- 2.39) in oligodendrogliomas.

The difference in median rCBV(max) between the two tumor types was significant (P < .0001).

CONCLUSION: The tumor rCBV(max) measurements derived from DSC MR imaging were significantly higher in low-grade oligodendrogliomas than in astrocytomas.

Our findings suggest that tumor rCBV(max) derived from DSC MR imaging can be used to distinguish between the two low-grade gliomas.

[MeSH-major] Magnetic Resonance Imaging / methods. Oligodendroglioma / pathology

[MeSH-minor] Adult. Aged. Blood Volume. Contrast Media. Diagnosis, Differential. Female. Humans. Male. Middle Aged

MedlinePlus Health Information. consumer health - MRI Scans.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15709123.001).

[ISSN] 0195-6108

[Journal-full-title] AJNR. American journal of neuroradiology

[ISO-abbreviation] AJNR Am J Neuroradiol

[Language] eng

[Grant] United States / NINDS NIH HHS / NS / K23 NS 45013

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.

[Publication-country] United States

[Chemical-registry-number] 0 / Contrast Media

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Retrospective review of prognostic factors, including 1p19q deletion, in low-grade oligodendrogliomas and a review of recent published works.

The purpose of the present study was to investigate potential prognostic factors in low-grade oligodendrogliomas (LGOs), particularly 1p19q deletion, due to its proven prognostic significance in anaplastic oligodendrogliomas.

All cases underwent central histopathological review and FISH testing for 1p19q status.

[MeSH-major] Brain Neoplasms. Oligodendroglioma

[MeSH-minor] Adult. Aged. Chromosomes, Human, Pair 19. Female. Gene Deletion. Genetic Predisposition to Disease / genetics. Humans. Incidence. Male. Middle Aged. New Zealand / epidemiology. Prognosis. Retrospective Studies. Risk Assessment. Risk Factors. Survival Analysis. Survival Rate

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19624298.001).

[ISSN] 1754-9485

[Journal-full-title] Journal of medical imaging and radiation oncology

[ISO-abbreviation] J Med Imaging Radiat Oncol

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review

[Publication-country] Australia

[Number-of-references] 30

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss.

PURPOSE: Loss of chromosome arms 1p and 19q is a molecular feature of oligodendroglial tumors characterized by responsiveness to chemotherapy and a favorable prognosis.

EXPERIMENTAL DESIGN: We analyzed 64 anaplastic oligodendrogliomas with 1p/19q loss or maintenance diagnosed at Massachusetts General Hospital and Brigham and Women's Hospital from 1996 to 2005; fluorescence in situ hybridization for 1p/19q and Ki-67 immunohistochemistry was done.

In agreement with previous studies, the group of anaplastic oligodendrogliomas with 1p/19q loss had significantly better progression-free survival and overall survival than anaplastic oligodendrogliomas with 1p/19q maintenance (P = 0.0009 and P < 0.0003, respectively).

Among anaplastic oligodendrogliomas with 1p/19q loss, those with polysomy showed shorter progression-free survival than those with 1p/19q loss without polysomy (P = 0.0048).

CONCLUSION: The presence of polysomy in anaplastic oligodendrogliomas with deletion of 1p/19q is a marker of earlier recurrence.

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Exp Clin Cancer Res. 1999 Sep;18(3):305-9 [10606174.001]

[Cites] Cancer Genet Cytogenet. 2008 Jul 15;184(2):77-86 [18617055.001]

[Cites] Genomics. 2000 Feb 15;64(1):44-50 [10708517.001]

[Cites] Genes Chromosomes Cancer. 2000 Sep;29(1):16-25 [10918389.001]

[Cites] Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):825-30 [11020580.001]

[Cites] Clin Cancer Res. 2001 Apr;7(4):839-45 [11309331.001]

[Cites] Cancer Res. 2001 Sep 15;61(18):6713-5 [11559541.001]

[Cites] Cancer Res. 2002 Jul 15;62(14):4100-8 [12124348.001]

[Cites] J Neuropathol Exp Neurol. 2003 Feb;62(2):111-26 [12578221.001]

[Cites] Cancer. 2003 Mar 1;97(5):1276-84 [12599236.001]

[Cites] J Neuropathol Exp Neurol. 2004 Apr;63(4):314-22 [15099021.001]

[Cites] Brain Pathol. 2004 Apr;14(2):121-30 [15193024.001]

[Cites] Cancer Res. 1994 Sep 1;54(17):4760-3 [8062276.001]

[Cites] Cancer. 1995 Nov 15;76(10):1809-13 [8625052.001]

[Cites] Cancer. 1996 Sep 1;78(5):1107-13 [8780550.001]

[Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]

[Cites] Clin Cancer Res. 2005 Feb 1;11(3):1119-28 [15709179.001]

[Cites] Cancer. 2005 Feb 15;103(4):802-9 [15637687.001]

[Cites] Cancer. 2005 Oct 1;104(7):1468-77 [16088966.001]

[Cites] J Clin Oncol. 2006 Mar 10;24(8):1246-52 [16525179.001]

[Cites] J Mol Diagn. 2006 May;8(2):268-76 [16645215.001]

[Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]

[Cites] Eur J Cancer. 2006 Oct;42(15):2499-503 [16914310.001]

[Cites] J Neuropathol Exp Neurol. 2006 Oct;65(10):988-94 [17021403.001]

[Cites] J Clin Oncol. 2006 Oct 10;24(29):4746-53 [16954518.001]

[Cites] Cancer Res. 2006 Oct 15;66(20):9852-61 [17047046.001]

[Cites] Neuro Oncol. 2007 Jul;9(3):314-8 [17435180.001]

[Cites] Oncogene. 2007 Jul 26;26(34):5010-6 [17311001.001]

[Cites] J Neuropathol Exp Neurol. 2008 Jan;67(1):1-15 [18091559.001]

[Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]

(PMID = 19808867.001).

[ISSN] 1078-0432

[Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research

[ISO-abbreviation] Clin. Cancer Res.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / CA057683-16; United States / NCI NIH HHS / CA / R01 CA057683; United States / NCI NIH HHS / CA / R01 CA057683-16

[Publication-type] Journal Article

[Publication-country] United States

[Other-IDs] NLM/ NIHMS160000; NLM/ PMC2818514

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Molecular cytogenetic stratification of recurrent oligodendrogliomas: utility of interphase fluorescence in situ hybridization (I-FISH).

In oligodendroglial brain tumours, losses of chromosomal material of the short arm of chromosome 1 and long arm of chromosome 19 have been shown to predict responsiveness to chemotherapy and prolonged patients' survival.

Therefore, the correct diagnosis of these genetic alterations in tumours of oligodendroglial origin is particularly important.

To detect deletions of 1p36 and/or 19q13.3 in oligodendroglial cells we used dual-colour I-FISH with locus-specific DNA probes.

We examined 16 patients with histologically proved oligodendrogliomas (5x oligodendroglioma, 9x anaplastic oligodendroglioma, 2x anaplastic oligoastrocytoma).

However, in six of them additional genetic alterations typical for high-grade astrocytoma were found, which could have negative influence on the prognosis.

A systematic molecular cytogenetic analysis may advance diagnosis, prognostic stratification, and targeted treatment of patients with brain tumours.

[MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / genetics. In Situ Hybridization, Fluorescence. Interphase / physiology. Oligodendroglioma / diagnosis. Oligodendroglioma / genetics

[MeSH-minor] Adult. Aged. Cell Nucleus / metabolism. Chromosome Aberrations. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 7 / genetics. Chromosomes, Human, Pair 9 / genetics. DNA Probes / metabolism. Female. Genome, Human / genetics. Humans. Male. Middle Aged. Prognosis

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17089917.001).

[ISSN] 0015-5500

[Journal-full-title] Folia biologica

[ISO-abbreviation] Folia Biol. (Praha)

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Czech Republic

[Chemical-registry-number] 0 / DNA Probes

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression.

BACKGROUND: Loss of heterozygosity (LOH) on chromosomes 1p and 19q has been associated with chemosensitivity and improved prognosis in patients with oligodendrogliomas.

Recent studies demonstrated that temozolomide (TMZ), an oral alkylating agent, has efficacy in the treatment of patients with progressive, low-grade oligodendroglioma (LGO).

METHODS: Adult patients with magnetic resonance imaging (MRI) findings and/or clinical deterioration compatible with progressive LGO were eligible for the study if they were radiotherapy-naive.

Clinical and MRI data were used to evaluate outcomes, and Kaplan-Meier estimates were used to assess the median time to tumor progression (TTP).

The 1p/19q status was analyzed from paired tumor-blood DNA samples using polymerase chain reaction-based microsatellite analysis.

MGMT protein expression was estimated semiquantitatively by immunohistochemistry using paraffin embedded tumor sections.

RESULTS: There were 28 patients who received treatment, and the median time from diagnosis to tumor progression was 33.5 months.

The authors suggest the possible use of MGMT immunostaining as a surrogate marker for predicting tumor chemosensitivity.

[MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Loss of Heterozygosity. O(6)-Methylguanine-DNA Methyltransferase / analysis. Oligodendroglioma / drug therapy

[MeSH-minor] Adolescent. Adult. Aged. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. DNA Repair. Disease Progression. Female. Humans. Immunohistochemistry. Male. Middle Aged

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] 2006 American Cancer Society

(PMID = 16541434.001).

[ISSN] 0008-543X

[Journal-full-title] Cancer

[ISO-abbreviation] Cancer

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Baseline 11C-methionine PET reflects the natural course of grade 2 oligodendrogliomas.

OBJECTIVES: The aim of the present study was to assess the usefulness of positron emission tomography (PET) with the amino acid tracer 11C-methionine (MET) as a predictor of time to progression (TTP) in patients with supratentorial grade 2 gliomas.

METHODS: Twenty-seven patients with glioma grade 2 subjected to a baseline PET scan received no anti-tumour treatment except for a diagnostic operation, and were followed until tumour progression.

Low uptake of MET was a predictor for long TTP in patients with oligodendrogliomas (p = 0.04) but not in astrocytomas/oligoastrocytomas.

Other predictors for long TTP were oligodendroglioma histology (p = 0.009) and seizures as presenting symptom (p = 0.03).

Favourable prognostic factors for overall survival were oligodendroglioma histology (p = 0.002) and good performance status (p = 0.03).

CONCLUSIONS: PET MET has a definite role in the therapeutic management of grade 2 gliomas.

[MeSH-major] Brain Neoplasms / radionuclide imaging. Carbon Radioisotopes. Methionine. Oligodendroglia / radionuclide imaging. Positron-Emission Tomography / methods

[MeSH-minor] Adolescent. Adult. Aged. Disease Progression. Female. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Predictive Value of Tests. Retrospective Studies. Time Factors

MedlinePlus Health Information. consumer health - Brain Tumors.

Hazardous Substances Data Bank. (L)-Methionine .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15978178.001).

[ISSN] 0161-6412

[Journal-full-title] Neurological research

[ISO-abbreviation] Neurol. Res.

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Carbon Radioisotopes; AE28F7PNPL / Methionine

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Diffuse low-grade oligodendrogliomas extend beyond MRI-defined abnormalities.

BACKGROUND: Imaging determinations of the spatial extent of diffuse low-grade gliomas (DLGGs) are of paramount importance in evaluating the risk-to-benefit ratio of surgical resection.

METHODS: We report a retrospective histologic and imaging correlation study in 16 adult patients who underwent serial stereotactic biopsies for the diagnosis of untreated supratentorial well-defined and non-contrast-enhanced DLGG, in whom biopsy samples were taken within and beyond (OutBSs) MRI-defined abnormalities.

MIB-1-positive cells were cycling isolated tumor cells, because 1) their morphologic characteristics reflected those of tumor cells, 2) the number of MIB-1-positive cells per square centimeter was significantly higher than that of controls, 3) the number of MIB-1-positive cells per square centimeter was positively correlated with the tumor growth fraction (p = 0.012), and 4) the number of MIB-1-positive cells per square centimeter in OutBSs decreased with distance from the tumor (p = 0.003).

CONCLUSIONS: This study demonstrates, using a multiscale correlative approach, that conventional MRI underestimates the actual spatial extent of diffuse low-grade gliomas (DLGGs), even when they are well delineated.

These results suggest that an extended resection of a margin beyond MRI-defined abnormalities, whenever feasible in noneloquent brain areas, might improve the outcome of DLGGs.

[MeSH-major] Brain / pathology. Brain Neoplasms / diagnosis. Magnetic Resonance Imaging. Oligodendroglioma / diagnosis

[MeSH-minor] Adolescent. Adult. Antibodies, Antinuclear / metabolism. Antibodies, Monoclonal / metabolism. Basic Helix-Loop-Helix Transcription Factors / metabolism. Biopsy / methods. Female. Glial Fibrillary Acidic Protein / metabolism. Humans. Image Enhancement / methods. Magnetic Resonance Spectroscopy / methods. Male. Middle Aged. Nerve Tissue Proteins / metabolism. Neurofilament Proteins / metabolism. Protons. Retrospective Studies. Statistics as Topic. Young Adult

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20498440.001).

[ISSN] 1526-632X

[Journal-full-title] Neurology

[ISO-abbreviation] Neurology

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Antibodies, Monoclonal; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Glial Fibrillary Acidic Protein; 0 / MIB-1 antibody; 0 / Nerve Tissue Proteins; 0 / Neurofilament Proteins; 0 / OLIG2 protein, human; 0 / Protons

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Functional MR imaging and oligodendrogliomas].

The localization of functional areas obtained from functional MRI (fMRI) is useful for patients suffering from tumors contiguous to eloquent brain areas. fRMI is an efficient tool in the strategy of treatment of low grade oligodendroglioamas in the rolandic area in intact or slightly impaired patients.

Direct integration of fMRI data into neuronavigation enables to better visualize and preserve eloquent brain areas.

[MeSH-major] Brain Neoplasms / physiopathology. Magnetic Resonance Imaging. Motor Cortex / physiopathology. Oligodendroglioma / physiopathology

[MeSH-minor] Adult. Feasibility Studies. Female. Humans. Intraoperative Care. Neurosurgical Procedures. Preoperative Care. Temporal Lobe / physiopathology. Temporal Lobe / radionuclide imaging. Temporal Lobe / surgery. Tomography, Emission-Computed, Single-Photon

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16292176.001).

[ISSN] 0028-3770

[Journal-full-title] Neuro-Chirurgie

[ISO-abbreviation] Neurochirurgie

[Language] fre

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] France

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Contributions of biological tumor parameters to the incorporation rate of L: -[methyl-(11)C] methionine into astrocytomas and oligodendrogliomas.

We compared the tumor uptake of (11)C-methionine (MET) with positron emission tomography (PET) with the results of a pathological analysis to examine the proliferative potential and microvessel density measured with immunostaining for MIB-1 and factor VIII, respectively, from 33 patients with glioma.

The MET uptake in oligodendrogliomas was significantly greater than that in grade 2 astrocytomas and comparable to those in grade 3 and 4 astrocytomas.

The MIB-1 index of oligodendroglioma meanwhile was comparable to that of grade 2 astrocytoma.

The microvessel area in oligodendroglioma was significantly greater than that in grade 2 astrocytomas and comparable to those in grade 3 and 4 astrocytomas.

An increase in the microvessel area in the oligodendrogliomas contributed to the higher MET uptake among the tumors with a low-proliferative index.

[MeSH-major] Astrocytoma / metabolism. Methionine / metabolism. Oligodendroglioma / metabolism

[MeSH-minor] Adult. Capillaries / metabolism. Capillaries / pathology. Carbon Radioisotopes. Cell Division. Factor VIII / metabolism. Female. Humans. Male. Microcirculation. Middle Aged. Neoplasm Staging. Positron-Emission Tomography

Hazardous Substances Data Bank. (L)-Methionine .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Clin Cancer Res. 2004 Nov 1;10(21):7163-70 [15534088.001]

[Cites] Cancer. 2001 Sep 15;92 (6):1541-9 [11745233.001]

[Cites] Eur J Nucl Med Mol Imaging. 2005 Jan;32(1):52-9 [15309332.001]

[Cites] Eur J Nucl Med Mol Imaging. 2002 Feb;29(2):176-82 [11926379.001]

[Cites] Acta Radiol. 1987 May-Jun;28(3):225-9 [2958026.001]

[Cites] AJR Am J Roentgenol. 1998 Dec;171(6):1479-86 [9843274.001]

[Cites] J Neurosurg. 1983 Feb;58(2):159-69 [6294260.001]

[Cites] AJNR Am J Neuroradiol. 2007 Nov-Dec;28(10 ):2005-7 [17905896.001]

[Cites] J Neurochem. 1987 Nov;49(5):1651-8 [3668544.001]

[Cites] Neurosurgery. 1995 Sep;37(3):478-82; discussion 483 [7501113.001]

[Cites] J Nucl Med. 1993 Nov;34(11):1936-43 [8229238.001]

[Cites] J Neurosurg. 2005 Sep;103(3):498-507 [16235683.001]

[Cites] Ann N Y Acad Sci. 1986;481:186-201 [3468857.001]

[Cites] Biochem J. 1997 Jun 1;324 ( Pt 2):535-41 [9182715.001]

[Cites] AJNR Am J Neuroradiol. 1996 Feb;17 (2):345-53 [8938309.001]

[Cites] Am J Physiol. 1976 Jan;230(1):94-8 [1251917.001]

[Cites] Radiology. 1988 Mar;166(3):823-7 [2829270.001]

[Cites] J Neurooncol. 2004 Jul;68(3):263-74 [15332331.001]

[Cites] Invest Radiol. 1999 Jun;34(6):427-34 [10353036.001]

[Cites] Neurosurg Rev. 1999 Dec;22(4):210-4 [10682929.001]

[Cites] J Nucl Med. 2000 Jul;41(7):1250-5 [10914918.001]

[Cites] Mayo Clin Proc. 1987 Jun;62(6):450-9 [3553757.001]

[Cites] Lab Invest. 1991 May;64(5):693-702 [1903170.001]

[Cites] Acta Radiol. 1990 Sep;31(5):417-29 [2261284.001]

[Cites] Radiology. 1994 Apr;191(1):41-51 [8134596.001]

[Cites] J Biol Chem. 1963 Nov;238:3686-99 [14109206.001]

[Cites] Surg Neurol. 2000 Sep;54(3):229-34; discussion 234 [11118569.001]

[Cites] J Comput Assist Tomogr. 1995 Jul-Aug;19(4):615-23 [7622696.001]

[Cites] J Biol Chem. 1995 Jun 23;270(25):14913-8 [7797470.001]

[Cites] Acta Radiol. 1987 Nov-Dec;28(6):673-81 [2962599.001]

[Cites] Clin Cancer Res. 2002 Sep;8(9):2933-8 [12231538.001]

[Cites] Cancer. 1996 Jan 15;77(2):362-72 [8625246.001]

[Cites] J Neurosurg. 1988 May;68(5):698-704 [2833587.001]

[Cites] Eur J Nucl Med Mol Imaging. 2003 Jun;30(6):868-73 [12692687.001]

[Cites] AJR Am J Roentgenol. 1986 Dec;147(6):1223-30 [3490758.001]

[Cites] Radiology. 1993 Jan;186(1):45-53 [8380108.001]

[Cites] J Nucl Med. 1991 Jul;32(7):1338-46 [1906093.001]

[Cites] Eur J Nucl Med. 2000 Jul;27(7):778-87 [10952489.001]

[Cites] J Neurol Neurosurg Psychiatry. 2004 Oct;75(10 ):1457-62 [15377696.001]

[Cites] J Nucl Med. 1997 Oct;38(10):1563-8 [9379193.001]

[Cites] AJNR Am J Neuroradiol. 2005 Feb;26(2):266-73 [15709123.001]

[Cites] Anticancer Res. 1997 Nov-Dec;17(6D):4747-53 [9494601.001]

(PMID = 19099197.001).

[ISSN] 1573-7373

[Journal-full-title] Journal of neuro-oncology

[ISO-abbreviation] J. Neurooncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Carbon Radioisotopes; 9001-27-8 / Factor VIII; AE28F7PNPL / Methionine

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Platelet-derived growth factor expression correlates with tumor grade and proliferative activity in human oligodendrogliomas.

BACKGROUND: For the last one and a half decade, it has been found that platelet-derived growth factor (PDGF) promotes glial tumor growth through autocrine and paracrine loops, by expression of PDGFalpha receptor (PDGFRalpha) on glioma cells and PDGFbeta receptor (PDGFRbeta) on proliferating endothelial cells.

However, studies on oligodendrogliomas, correlating expression of PDGF and its receptor with tumor grade and proliferative activity, through MIB-1 labeling index (LI) are relatively few as compared to astroglial counterpart.

METHODS: Formalin-fixed paraffin-embedded tissues from 55 cases of oligodendrogliomas (34 World Health Organization [WHO] grade II and 21 WHO grade III tumors) were subjected to immunohistochemistry.

MIB-1 LI was calculated, and a semiquantitative scoring system for expression of PDGF and PDGFRalpha was used.

The PDGF expression scores had a positive correlation with MIB-1 LI, irrespective of tumor grade (Pearson's correlation coefficient, r = 0.566; P < .001).

CONCLUSIONS: The results of this study showed that MIB-1 LI is a rapid and cost-effective modality for predicting tumor grade in oligodendrogliomas.

Immunohistochemistry for PDGF was found to be useful in differentiating various grades of oligodendroglioma, and therefore, it may be involved in tumor cell proliferation and malignant transformation.

Platelet-derived growth factor receptor alpha, although expressed in oligodendroglial neoplasms, was not found to be useful in predicting tumor grade.

[MeSH-major] Antibodies, Antinuclear / metabolism. Antibodies, Monoclonal / metabolism. Biomarkers, Tumor / metabolism. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Oligodendroglioma / metabolism. Oligodendroglioma / pathology. Platelet-Derived Growth Factor / metabolism

[MeSH-minor] Adolescent. Adult. Aged. Cell Proliferation. Child. Cost-Benefit Analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry / economics. Immunohistochemistry / methods. Male. Middle Aged. Predictive Value of Tests. Retrospective Studies. Sensitivity and Specificity. Time Factors. Young Adult

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19559929.001).

[ISSN] 1879-3339

[Journal-full-title] Surgical neurology

[ISO-abbreviation] Surg Neurol

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / MIB-1 antibody; 0 / Platelet-Derived Growth Factor

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Caveolin-1 expression is variably displayed in astroglial-derived tumors and absent in oligodendrogliomas: concrete premises for a new reliable diagnostic marker in gliomas.

The distribution of caveolae within the normal brain and in brain tumors is controversial.

In the present study, we describe the expression of caveolin-1 (cav-1) in 64 brain tumors of different grade, of either astroglial or oligodendroglial origin.

All studied astrocitomas of any grade (from II to IV) were cav-1 positive, displaying staining patterns and intensity specifically associated to the different tumor grades.

In anaplastic astrocytomas, a less intense membrane staining or a cytoplasmic dotlike immunoreactivity were present, the latter being almost the exclusive pattern observed in diffuse astrocitomas grade II.

In contrast to astroglial tumors, the striking totality of grade II oligodendrogliomas and the large majority of grade III were lacking cav-1 expression.

In conclusion, among astroglial tumors cav-1 expression varies in distribution, pattern, and intensity specifically according to tumor types and grades.

The association between tumor progression and a more structured membranous pattern of cav-1 expression could suggest the hypothesis of a neoplastic shift towards a mesenchymal phenotype, whose behavioral and biologic significance worth further studies.

Finally, the lack of cav-1 immunoreactivity in oligodendrogliomas suggests its concrete application as a useful diagnostic marker.

[MeSH-major] Astrocytes / metabolism. Biomarkers, Tumor / metabolism. Brain Neoplasms / metabolism. Caveolin 1 / metabolism. Glioblastoma / metabolism. Oligodendroglioma / metabolism

[MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Count. Cell Line, Tumor. Cell Separation. Chromosome Deletion. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Disease Progression. Flow Cytometry. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17460461.001).

[ISSN] 0147-5185

[Journal-full-title] The American journal of surgical pathology

[ISO-abbreviation] Am. J. Surg. Pathol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Caveolin 1

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy.

Based on studies relating to anaplastic oligodendroglioma (OG) chemosensitivity and benefit of time to progression or overall survival, chemotherapy for pure OG has been proposed.

Several studies have reported the efficacy of various chemotherapeutic agents in a small number of patients with low-grade gliomas, e.g. pure astrocytomas, OG or mixed histologies.

We report the outcome of 33 consecutive patients with pure low-grade OG diagnosed between 1990 and 2006 systematically treated for residual or non-removable tumor with PCV chemotherapy regimen as the front-line treatment after surgery.

All the tumors were low grade (grade II) pure OG according to the WHO classification.

Response was evaluated by clinical assessment and brain magnetic resonance imaging.

Up-front chemotherapy with PCV regimen is a good treatment for symptomatic pure low-grade OG, as it increases the number of progression-free patients and time to progression.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Oligodendroglioma / drug therapy

[MeSH-minor] Adult. Disease Progression. Disease-Free Survival. Female. Humans. Lomustine / therapeutic use. Magnetic Resonance Imaging. Male. Middle Aged. Procarbazine / therapeutic use. Treatment Outcome. Vincristine / therapeutic use

MedlinePlus Health Information. consumer health - Brain Tumors.

Hazardous Substances Data Bank. LOMUSTINE .

Hazardous Substances Data Bank. VINCRISTINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17388986.001).

[ISSN] 1468-1331

[Journal-full-title] European journal of neurology

[ISO-abbreviation] Eur. J. Neurol.

[Language] eng

[Publication-type] Clinical Trial; Journal Article

[Publication-country] England

[Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; PCV protocol

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study.

PURPOSE: This is one of a few studies that have explored the value of baseline symptoms and health-related quality of life (HRQOL) in predicting survival in patients with brain cancer.

PATIENTS AND METHODS: Baseline HRQOL scores (from the European Organisation for Research and Treatment of Cancer [EORTC] Quality of Life Questionnaire C30 and the EORTC Brain Cancer Module) were examined in 247 patients with anaplastic oligodendrogliomas to determine the relationship with overall survival by using Cox proportional hazards regression models.

[MeSH-major] Brain Neoplasms / mortality. Oligodendroglioma / mortality. Quality of Life

[MeSH-minor] Adult. Female. Health Status. Humans. Male. Middle Aged. Prognosis. Survival Analysis

Genetic Alliance. consumer health - Brain Cancer.

MedlinePlus Health Information. consumer health - Brain Tumors.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18089867.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / 5U10CA11488-30; United States / NCI NIH HHS / CA / 5U10CA11488-31; United States / NCI NIH HHS / CA / 5U10CA11488-32; United States / NCI NIH HHS / CA / 5U10CA11488-33; United States / NCI NIH HHS / CA / 5U10CA11488-34

[Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas.

Outcomes analyzed include overall survival (OS), progression-free survival (PFS), and treatment toxicity greater than or equal to grade 3.

SEARCH STRATEGY: Cochrane Central Register for Controlled Trials (CENTRAL, Issue 4,2006), MEDLINE (1966 to 2006) and EMBASE (1988 to 2006) were searched.

Tumors with 1p and 19q co-deletions are associated with better OS and may indicate a more chemo-responsive tumor.

[MeSH-major] Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Oligodendroglioma / drug therapy

[MeSH-minor] Adult. Chemotherapy, Adjuvant. Humans. Randomized Controlled Trials as Topic

[Email] Email this result item

Email the results to the following email address:   [X] Close

[UpdateIn] Cochrane Database Syst Rev. 2014;5:CD007104 [24833028.001]

(PMID = 18425979.001).

[ISSN] 1469-493X

[Journal-full-title] The Cochrane database of systematic reviews

[ISO-abbreviation] Cochrane Database Syst Rev

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] England

[Number-of-references] 11

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial.

PURPOSE: Anaplastic oligodendrogliomas are more responsive to chemotherapy than high-grade astrocytomas.

We investigated, in a multicenter randomized controlled trial, whether adjuvant procarbazine, lomustine, and vincristine (PCV) chemotherapy improves overall survival (OS) in newly diagnosed patients with anaplastic oligodendrogliomas or anaplastic oligoastrocytomas.

In the RT arm, 82% of patients with tumor progression received chemotherapy.

CONCLUSION: Adjuvant PCV chemotherapy does not prolong OS but does increase PFS in anaplastic oligodendroglioma.

Combined loss of 1p/19q identifies a favorable subgroup of oligodendroglial tumors.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Oligodendroglioma / drug therapy

[MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. Dose Fractionation. Female. Humans. Lomustine / therapeutic use. Loss of Heterozygosity. Male. Middle Aged. Procarbazine / therapeutic use. Survival Analysis. Vincristine / therapeutic use

MedlinePlus Health Information. consumer health - Brain Tumors.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

Hazardous Substances Data Bank. LOMUSTINE .

Hazardous Substances Data Bank. VINCRISTINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Nat Clin Pract Oncol. 2007 Feb;4(2):78-9 [17228307.001]

[CommentIn] J Clin Oncol. 2006 Jun 20;24(18):2689-90 [16782906.001]

[CommentIn] Curr Neurol Neurosci Rep. 2007 May;7(3):189-90 [17488583.001]

[CommentIn] Nat Clin Pract Neurol. 2007 Jan;3(1):14-5 [17205067.001]

(PMID = 16782911.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; PCV protocol

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial.

PURPOSE: Chemotherapy with alkylating agents is of proven efficacy in recurrent anaplastic oligodendroglioma (AO) with reported response rates ranging between 50% and 70%.

This study evaluated the response and time to tumor progression of newly diagnosed AO initially treated with TMZ.

Treatment was given every 28 days for 5 days at a starting dose of 200 mg/m2/d and was continued for 24 cycles unless toxicity or tumor progression required withdrawal of TMZ.

The objective response rate was 75%, and median time to tumor progression was 24 months.

TMZ was well tolerated with only two events of grade 3/4 hematological toxicity.

[MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Oligodendroglioma / drug therapy

[MeSH-minor] Adult. Disease-Free Survival. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Treatment Outcome

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Expert Opin Pharmacother. 2004 Feb;5(2):295-306 [14996626.001]

[Cites] J Neurooncol. 2003 Nov;65(2):127-34 [14686732.001]

[Cites] J Clin Oncol. 2001 May 1;19(9):2449-55 [11331324.001]

[Cites] Neurology. 1998 Oct;51(4):1140-5 [9781544.001]

[Cites] J Clin Oncol. 1999 Sep;17 (9):2762-71 [10561351.001]

[Cites] J Clin Oncol. 2003 Jul 1;21(13):2525-8 [12829671.001]

[Cites] Neurology. 2004 May 25;62(10 ):1783-7 [15159478.001]

[Cites] Recent Results Cancer Res. 1994;135:127-33 [8047688.001]

[Cites] Ann Oncol. 2003 Apr;14 (4):599-602 [12649108.001]

[Cites] Semin Oncol. 2004 Oct;31(5):645-52 [15497117.001]

[Cites] J Clin Oncol. 1994 Oct;12(10):2013-21 [7931469.001]

(PMID = 16855865.001).

[ISSN] 0167-594X

[Journal-full-title] Journal of neuro-oncology

[ISO-abbreviation] J. Neurooncol.

[Language] eng

[Publication-type] Clinical Trial; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; YF1K15M17Y / temozolomide

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Immunohistochemical evaluation of the microvascular density through the expression of TGF-beta (CD 105/endoglin) and CD 34 receptors and expression of the vascular endothelial growth factor (VEGF) in oligodendrogliomas.

The determinants of this process, the growth factors and the vascular endothelial receptors have brought a potential in the tumor prognostic determination as well as perspectives of "targets" for antiangiogenic therapy.

In oligodendrogliomas (OL), angiogenesis is little known and/or has generated conflicting results.

There was expression in <10% of tumor cells and/or staining of weak intensity in 15 (50.0%), >10% of cells and moderate intensity staining in 1 (3.33%), and negative expression in 14 (46.67%).

If present, the expression was restricted to tumor and endothelial cells.

The mean +/- SD MVD-CD105 and MVD-CD34 were 10.83 +/- 2.24 and 11.00 +/- 2.76 in OL (P = 0.086; r = 0.319); 10.00 +/- 2.00 and 10.40 +/- 3.02 in OL grade II (n = 15) (P = 0.547; r = 0.105), and 11.67 +/- 2.22 and 11.53 +/- 2.45 in OL grade III (n = 15) (P = 0.817; r = 0.551), respectively.

The absence of correlation between DMV-CD105, DMV-CD34 and tumor grades suggests that anti-CD105 and anti-CD34 antibodies have different vascular specificities.

MVD-CD105 was greater in OL grade III than in OL grade II (P = 0.0032), indicating an increase in the vascular neoformation, something which must be evaluated as a possible prognostic factor in OL.

[MeSH-major] Antigens, CD / biosynthesis. Antigens, CD34 / biosynthesis. Brain Neoplasms / blood supply. Neovascularization, Pathologic / pathology. Oligodendroglioma / blood supply. Receptors, Cell Surface / biosynthesis. Vascular Endothelial Growth Factor A / biosynthesis

[MeSH-minor] Adolescent. Adult. Aged. Child. Endothelium, Vascular / metabolism. Female. Humans. Immunohistochemistry. Male. Middle Aged

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18181830.001).

[ISSN] 0919-6544

[Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology

[ISO-abbreviation] Neuropathology

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Australia

[Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD34; 0 / ENG protein, human; 0 / Receptors, Cell Surface; 0 / Vascular Endothelial Growth Factor A

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Factors affecting prognosis of patients with intracranial anaplastic oligodendrogliomas: a single institutional review of 70 patients.

Anaplastic oligodendroglioma (AO) is an uncommon intracranial tumor and prognosis is poor.

[MeSH-major] Brain Neoplasms / diagnosis. Oligodendroglioma / diagnosis

[MeSH-minor] Adolescent. Adult. Age Factors. Aged. Child. Drug Therapy. Female. Humans. Karnofsky Performance Status. Longitudinal Studies. Magnetic Resonance Imaging / methods. Male. Middle Aged. Prognosis. Radiotherapy. Retrospective Studies. Tomography Scanners, X-Ray Computed. Young Adult

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Surg Neurol. 2002 Aug;58(2):111-7; discussion 117 [12453646.001]

[Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]

[Cites] Oncology. 2003;65(3):259-66 [14657600.001]

[Cites] Neurosurgery. 1999 Dec;45(6):1279-91; discussion 191 [10598694.001]

[Cites] Neurosurgery. 1994 Jun;34(6):959-66; discussion 966 [8084406.001]

[Cites] J Neuropathol Exp Neurol. 2003 Feb;62(2):111-26 [12578221.001]

[Cites] Am J Clin Oncol. 2000 Apr;23(2):170-5 [10776979.001]

[Cites] Clin Cancer Res. 2001 Apr;7(4):839-45 [11309331.001]

[Cites] Surg Neurol. 2003 Nov;60(5):443-56 [14572971.001]

[Cites] Chin Med J (Engl). 2008 Jun 20;121(12):1072-5 [18706219.001]

[Cites] Neurology. 2004 May 25;62(10 ):1783-7 [15159478.001]

[Cites] J Neurooncol. 2002 Sep;59(3):231-7 [12241120.001]

[Cites] J Neuropathol Exp Neurol. 2007 Jun;66(6):545-51 [17549014.001]

[Cites] Cancer. 1987 Apr 1;59(7):1345-52 [3545437.001]

[Cites] J Neurooncol. 2006 Sep;79(2):153-7 [16855865.001]

[Cites] J Neuropathol Exp Neurol. 2003 Nov;62(11):1118-28 [14656070.001]

[Cites] J Neurooncol. 2006 Sep;79(2):159-68 [16821091.001]

[Cites] J Neurooncol. 2005 Nov;75(2):189-93 [16132506.001]

[Cites] Oncogene. 2002 Jun 6;21(25):3961-8 [12037678.001]

(PMID = 20195700.001).

[ISSN] 1573-7373

[Journal-full-title] Journal of neuro-oncology

[ISO-abbreviation] J. Neurooncol.

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131.

The primary objectives of this phase II study were to evaluate the use of preirradiation temozolomide followed by concurrent temozolomide and radiotherapy (RT) in patients with newly diagnosed anaplastic oligodendroglioma (AO) and mixed anaplastic oligoastrocytoma (MOA).

Tumor tissue was analyzed for the presence of chromosomal deletions on 1p and 19q and for MGMT-promoter methylation.

The worst nonhematological toxicity was grade 4 in three patients (8%).

There were no grade 4 nonhematological toxicities during the concurrent chemotherapy and RT.

[MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Astrocytoma / therapy. Brain Neoplasms / therapy. Dacarbazine / analogs & derivatives. Neoplasm Recurrence, Local / therapy. Oligodendroglioma / therapy

[MeSH-minor] Adolescent. Adult. Aged. Chromosome Deletion. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Combined Modality Therapy. DNA Methylation. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Dose Fractionation. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Prognosis. Promoter Regions, Genetic. Survival Rate. Treatment Outcome. Tumor Suppressor Proteins / genetics. Young Adult

MedlinePlus Health Information. consumer health - Brain Tumors.

COS Scholar Universe. author profiles.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cancer Treat Rev. 1997 Jan;23(1):35-61 [9189180.001]

[Cites] J Clin Oncol. 1994 Oct;12(10):2013-21 [7931469.001]

[Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]

[Cites] Oncogene. 1999 Jul 15;18(28):4144-52 [10435596.001]

[Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]

[Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]

[Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]

[Cites] Cancer Res. 2006 Oct 15;66(20):9852-61 [17047046.001]

[Cites] Neuro Oncol. 2007 Jul;9(3):314-8 [17435180.001]

[Cites] J Neurosurg. 1996 Oct;85(4):602-7 [8814163.001]

[Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]

[Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]

[Cites] Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):825-30 [11020580.001]

[Cites] Clin Cancer Res. 2001 Apr;7(4):839-45 [11309331.001]

[Cites] J Clin Oncol. 2001 May 1;19(9):2449-55 [11331324.001]

[Cites] Cancer Res. 2001 Jun 15;61(12):4689-92 [11406538.001]

[Cites] Neurology. 2001 Jul 24;57(2):340-2 [11468326.001]

[Cites] Lancet Oncol. 2001 Sep;2(9):552-60 [11905710.001]

[Cites] J Neurooncol. 2003 Feb;61(3):267-73 [12675321.001]

[Cites] J Clin Oncol. 2003 Jul 1;21(13):2525-8 [12829671.001]

[Cites] J Neurooncol. 2003 Sep;64(3):271-8 [14558604.001]

[Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]

[Cites] J Neurosurg. 1985 Dec;63(6):881-9 [4056902.001]

[Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]

[Cites] Cancer Res. 1998 Oct 1;58(19):4363-7 [9766665.001]

(PMID = 18779504.001).

[ISSN] 1522-8517

[Journal-full-title] Neuro-oncology

[ISO-abbreviation] Neuro-oncology

[Language] eng

[Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Tumor Suppressor Proteins; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes

[Other-IDs] NLM/ PMC2718988

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Predictive value of multimodality MRI using conventional, perfusion, and spectroscopy MR in anaplastic transformation of low-grade oligodendrogliomas.

The aim of our study was to evaluate the role of proton magnetic resonance (MR) spectroscopy and MR perfusion in the follow-up of low-grade gliomas, since conventional MR imaging (MRI) is not reliable in detecting the passage from a low- to high-grade tumor.

Twenty-one patients with a World Health Organisation (WHO) grade II glioma were followed up using proton MR spectroscopy, perfusion, and conventional MRIs.

The mean annual growth of low-grade glioma was 3.65 mm.

Proton magnetic resonance spectroscopy should be recommended in the follow-up of low-grade gliomas since the choline/creatine ratio can predict anaplastic transformation before perfusion abnormalities, with high positive predictive value of 83%.

[MeSH-major] Brain Neoplasms / pathology. Diffusion Magnetic Resonance Imaging / methods. Magnetic Resonance Spectroscopy / methods. Oligodendroglioma / pathology

[MeSH-minor] Adult. Aged. Cerebrovascular Circulation / physiology. Choline / metabolism. Contrast Media. Creatine / metabolism. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Protons. ROC Curve. Regional Blood Flow

MedlinePlus Health Information. consumer health - Brain Tumors.

Hazardous Substances Data Bank. CREATINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] AJR Am J Roentgenol. 2007 Jan;188(1):204-12 [17179366.001]

[Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]

[Cites] AJNR Am J Neuroradiol. 2005 Apr;26(4):784-90 [15814921.001]

[Cites] AJNR Am J Neuroradiol. 2008 Nov;29(10):1872-7 [18719036.001]

[Cites] Radiology. 2008 Apr;247(1):170-8 [18372467.001]

[Cites] AJR Am J Roentgenol. 1998 Dec;171(6):1479-86 [9843274.001]

[Cites] J Neurosurg. 2007 Apr;106(4):660-6 [17432719.001]

[Cites] Neuro Oncol. 2006 Jan;8(1):12-26 [16443944.001]

[Cites] AJNR Am J Neuroradiol. 2008 Mar;29(3):458-63 [18065512.001]

[Cites] J Neurooncol. 2000 Dec;50(3):215-26 [11263501.001]

[Cites] Radiologe. 2007 Sep;47(9):812-8 [16924439.001]

[Cites] J Neurosurg. 2003 Jan;98(1):74-81 [12546355.001]

[Cites] Cancer. 2004 Nov 15;101(10):2293-9 [15476282.001]

[Cites] J Neurooncol. 2009 May;92(3):317-35 [19357959.001]

[Cites] Life Sci. 1996;58(22):1929-35 [8637421.001]

[Cites] Neuroradiology. 2005 Dec;47(12):887-91 [16133483.001]

[Cites] NMR Biomed. 1991 Apr;4(2):47-52 [1650241.001]

[Cites] Neurology. 2002 Sep 24;59(6):947-9 [12297589.001]

[Cites] Ann Neurol. 2003 Apr;53(4):524-8 [12666121.001]

[Cites] J Neurooncol. 2003 Jul;63(3):233-45 [12892229.001]

[Cites] J Neurosci. 1993 Mar;13(3):981-9 [8441018.001]

[Cites] AJNR Am J Neuroradiol. 2003 Nov-Dec;24(10):1989-98 [14625221.001]

[Cites] Ann Neurol. 2006 Sep;60(3):380-3 [16983683.001]

[Cites] Neurosurgery. 2001 Oct;49(4):823-9 [11564242.001]

[Cites] Neurol Res. 2009 Nov;31(9):931-9 [19215664.001]

[Cites] AJNR Am J Neuroradiol. 2008 Apr;29(4):688-93 [18184842.001]

[Cites] AJNR Am J Neuroradiol. 2001 Apr;22(4):604-12 [11290466.001]

[Cites] Eur Neurol. 2007;58(4):198-209 [17823533.001]

[Cites] J Neurosurg. 1997 Oct;87(4):516-24 [9322842.001]

(PMID = 19727562.001).

[ISSN] 1573-7373

[Journal-full-title] Journal of neuro-oncology

[ISO-abbreviation] J. Neurooncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Contrast Media; 0 / Protons; MU72812GK0 / Creatine; N91BDP6H0X / Choline

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss.

Deletions of portions of chromosomes 1p and 19q are closely associated with the oligodendroglioma histologic phenotype.

We report 5 cases (World Health Organization grade III) in which metaphase cytogenetics identified a derivative chromosome consisting of what appears to be the whole arms of 1q and 19p forming a der(1;19)(q10;p10).

Subsequent loss of the der(1;19)(p10;q10) then results in the simultaneous 1p and 19q loss observed in oligodendroglioma with retention of the der(1;19)(q10;p10) seen in these cases.

[MeSH-major] Brain Neoplasms / genetics. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. Oligodendroglioma / genetics. Translocation, Genetic

[MeSH-minor] Adult. Chromosome Aberrations. Chromosome Deletion. Female. Humans. In Situ Hybridization, Fluorescence. Loss of Heterozygosity. Male

MedlinePlus Health Information. consumer health - Brain Tumors.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17021403.001).

[ISSN] 0022-3069

[Journal-full-title] Journal of neuropathology and experimental neurology

[ISO-abbreviation] J. Neuropathol. Exp. Neurol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The role of radiotherapy in the treatment of newly diagnosed supratentorial low-grade oligodendrogliomas: comparative analysis with immediate radiotherapy versus surgery alone.

PURPOSE: The purpose of this study was to evaluate the role of immediate postoperative radiotherapy (RT) in adult patients with a low-grade oligodendroglioma (LODG).

All patients were closely observed until tumor progression or death with frequent work-ups including neurological examinations and MRI.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Lancet. 2005 Sep 17-23;366(9490):985-90 [16168780.001]

[Cites] Neurology. 2000 Apr 11;54(7):1442-8 [10751254.001]

[Cites] Can J Neurol Sci. 1999 Feb;26(1):18-22 [10068802.001]

[Cites] Eur J Cancer. 1998 Nov;34(12):1902-9 [10023313.001]

[Cites] Can J Neurol Sci. 1997 Nov;24(4):313-9 [9398978.001]

[Cites] J Neurooncol. 1997 Aug;34(1):37-59 [9210052.001]

[Cites] Cancer. 1997 Apr 1;79(7):1381-93 [9083161.001]

[Cites] Int J Radiat Oncol Biol Phys. 1996 Oct 1;36(3):549-56 [8948338.001]

[Cites] Neurosurgery. 1994 Dec;35(6):1018-34; discussion 1034-5 [7885546.001]

[Cites] Int J Radiat Oncol Biol Phys. 1994 Oct 15;30(3):567-73 [7928487.001]

[Cites] Cancer. 1993 Jun 15;71(12):4002-6 [8508366.001]

[Cites] Radiology. 1993 Feb;186(2):569-72 [8421767.001]

[Cites] Mayo Clin Proc. 1987 Jun;62(6):435-49 [2437411.001]

[Cites] J Neurosurg. 1988 May;68(5):684-8 [3357029.001]

[Cites] J Neurosurg. 1987 Aug;67(2):224-30 [3598683.001]

[Cites] J Neurosurg. 1985 Dec;63(6):881-9 [4056902.001]

[Cites] Am J Clin Oncol. 2003 Jun;26(3):e60-6 [12796617.001]

[Cites] Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1405-9 [12459363.001]

[Cites] Lancet. 2002 Nov 2;360(9343):1361-8 [12423981.001]

[Cites] J Clin Oncol. 2002 May 1;20(9):2267-76 [11980997.001]

[Cites] Am J Clin Oncol. 2000 Apr;23(2):170-5 [10776979.001]

[Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):797-802 [15936562.001]

(PMID = 19809562.001).

[ISSN] 1598-2998

[Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association

[ISO-abbreviation] Cancer Res Treat

[Language] eng

[Publication-type] Journal Article

[Publication-country] Korea (South)

[Other-IDs] NLM/ PMC2757663

[Keywords] NOTNLM ; Brain neoplasms / Oligodendroglioma / Radiotherapy

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Diagnostic and prognostic molecular markers in common adult gliomas.

The majority of primary CNS tumors in adults are comprised of gliomas (astrocytomas, oligodendrogliomas and ependymomas).

In this article, we summarize the findings of important, published biomarker studies in adult gliomas and provide an overview of the practical uses of these markers in the clinical setting, as well as the current understanding of molecular gliomagenesis.

[MeSH-major] Biomarkers, Tumor / metabolism. Central Nervous System Neoplasms / diagnosis. Central Nervous System Neoplasms / therapy. Glioma / diagnosis. Glioma / therapy

[MeSH-minor] Adult. Clinical Trials as Topic. Gene Expression Profiling. Humans. Prognosis. Treatment Outcome

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20629512.001).

[ISSN] 1744-8352

[Journal-full-title] Expert review of molecular diagnostics

[ISO-abbreviation] Expert Rev. Mol. Diagn.

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Biomarkers, Tumor